CA2759706A1 - Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors - Google Patents
Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors Download PDFInfo
- Publication number
- CA2759706A1 CA2759706A1 CA2759706A CA2759706A CA2759706A1 CA 2759706 A1 CA2759706 A1 CA 2759706A1 CA 2759706 A CA2759706 A CA 2759706A CA 2759706 A CA2759706 A CA 2759706A CA 2759706 A1 CA2759706 A1 CA 2759706A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- isobutyl
- cyclohexylmethyl
- phenyl
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 aromatic piperazinyl azetidinyl amides Chemical class 0.000 title claims description 24
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title description 38
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title description 38
- 229940127470 Lipase Inhibitors Drugs 0.000 title description 3
- 125000001072 heteroaryl group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 289
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 98
- 208000035475 disorder Diseases 0.000 claims abstract description 50
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 43
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 40
- 208000002193 Pain Diseases 0.000 claims abstract description 28
- 230000005764 inhibitory process Effects 0.000 claims abstract description 28
- 230000036407 pain Effects 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 29
- 208000004296 neuralgia Diseases 0.000 claims description 26
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 20
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 18
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 18
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 208000004454 Hyperalgesia Diseases 0.000 claims description 15
- 208000021722 neuropathic pain Diseases 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 206010065390 Inflammatory pain Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000009610 hypersensitivity Effects 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 206010053552 allodynia Diseases 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 6
- 230000002981 neuropathic effect Effects 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 208000009935 visceral pain Diseases 0.000 claims description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 5
- 239000000203 mixture Substances 0.000 abstract description 25
- 239000012453 solvate Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 206010029240 Neuritis Diseases 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 208000035154 Hyperesthesia Diseases 0.000 description 8
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 8
- 239000002621 endocannabinoid Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 208000015114 central nervous system disease Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- KWKZCGMJGHHOKJ-PDXKBQATSA-N methoxy arachidonyl fluorophosphonate Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCC[P@@](F)(=O)OC KWKZCGMJGHHOKJ-PDXKBQATSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- YSYHKAYPWAJWOF-UHFFFAOYSA-N (2-cyclohexyl-1,3-benzoxazol-6-yl)-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N=C(C3CCCCC3)OC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 YSYHKAYPWAJWOF-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- IAVHPTVBDVEOKB-UHFFFAOYSA-N [2-(3-fluorophenyl)-1,3-benzoxazol-7-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound FC1=CC=CC(C=2OC3=C(C(=O)N4CC(C4)N4CCN(CC4)C=4N=CC=CC=4)C=CC=C3N=2)=C1 IAVHPTVBDVEOKB-UHFFFAOYSA-N 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NRZNTGUFHSJBTD-HKOYGPOVSA-N 2-[2-(2-methoxyethoxy)ethoxy]ethyl (e)-2-cyano-3-(6-piperidin-1-ylnaphthalen-2-yl)prop-2-enoate Chemical compound C1=CC2=CC(/C=C(C(=O)OCCOCCOCCOC)\C#N)=CC=C2C=C1N1CCCCC1 NRZNTGUFHSJBTD-HKOYGPOVSA-N 0.000 description 4
- VNDWQCSOSCCWIP-UHFFFAOYSA-N 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Chemical compound C1=2C=CNC(=O)C=2C2=CC(F)=CC=C2C2=C1NC(C(C)(C)C)=N2 VNDWQCSOSCCWIP-UHFFFAOYSA-N 0.000 description 4
- LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- UKDGFEGSBPNRME-UHFFFAOYSA-N [1-(2,2-dimethylpropyl)-2-phenylindol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC(C)(C)C)C(C=3C=CC=CC=3)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 UKDGFEGSBPNRME-UHFFFAOYSA-N 0.000 description 4
- JZLSGVQLASJYPM-UHFFFAOYSA-N [1-(2-methylpropyl)-2-phenylindol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC(C)C)C(C=3C=CC=CC=3)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 JZLSGVQLASJYPM-UHFFFAOYSA-N 0.000 description 4
- SRKXYTODUWWUQK-UHFFFAOYSA-N [1-(cyclohexylmethyl)-2-(phenoxymethyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC3CCCCC3)C(COC=3C=CC=CC=3)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 SRKXYTODUWWUQK-UHFFFAOYSA-N 0.000 description 4
- MEAFAMDMWFATKK-UHFFFAOYSA-N [2-(4-fluorophenyl)-1,3-benzoxazol-7-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1=NC2=CC=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=C2O1 MEAFAMDMWFATKK-UHFFFAOYSA-N 0.000 description 4
- ZESPLPSMAHGDBK-UHFFFAOYSA-N [2-(4-methoxyphenyl)-1,3-benzoxazol-7-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=C2O1 ZESPLPSMAHGDBK-UHFFFAOYSA-N 0.000 description 4
- UFCZKCQGXLMIMZ-UHFFFAOYSA-N [2-[(4-methylphenyl)methyl]-1-(2-methylpropyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C2=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=CC=C2N(CC(C)C)C=1CC1=CC=C(C)C=C1 UFCZKCQGXLMIMZ-UHFFFAOYSA-N 0.000 description 4
- MTUMVVIQTVMHEW-UHFFFAOYSA-N [2-benzyl-1-(cyclohexylmethyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC3CCCCC3)C(CC=3C=CC=CC=3)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 MTUMVVIQTVMHEW-UHFFFAOYSA-N 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 229930003827 cannabinoid Natural products 0.000 description 4
- 239000003557 cannabinoid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- SLTOJZPUDOLWKT-UHFFFAOYSA-N 2-cyclohexyl-1,3-benzoxazole-6-carboxylic acid Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1CCCCC1 SLTOJZPUDOLWKT-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 3
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- IIZBSOXJCGKJPB-UHFFFAOYSA-N [1-(2,2-dimethylpropyl)-2-(phenoxymethyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C2=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=CC=C2N(CC(C)(C)C)C=1COC1=CC=CC=C1 IIZBSOXJCGKJPB-UHFFFAOYSA-N 0.000 description 3
- GIMDIYNOOHMMKV-UHFFFAOYSA-N [1-(2-methylpropyl)-2-(phenoxymethyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C2=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=CC=C2N(CC(C)C)C=1COC1=CC=CC=C1 GIMDIYNOOHMMKV-UHFFFAOYSA-N 0.000 description 3
- ZQCOUDWRSUQKEY-UHFFFAOYSA-N [1-(cyclohexylmethyl)-2-propylindol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound CCCC1=CC2=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=CC=C2N1CC1CCCCC1 ZQCOUDWRSUQKEY-UHFFFAOYSA-N 0.000 description 3
- MFKWVGQETFPGTM-UHFFFAOYSA-N [2-(4-methylphenyl)-1-(2-methylpropyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC(C)C)C(C=3C=CC(C)=CC=3)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 MFKWVGQETFPGTM-UHFFFAOYSA-N 0.000 description 3
- WBXAUCKRTZLHHD-UHFFFAOYSA-N [2-(cyclopentylmethyl)-1-methylindol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C2=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=CC=C2N(C)C=1CC1CCCC1 WBXAUCKRTZLHHD-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 230000020341 sensory perception of pain Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- SGZSRNRGHRRIKH-UHFFFAOYSA-N (2-cyclohexyl-1,3-benzoxazol-6-yl)-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=CC=C(N=C(O2)C3CCCCC3)C2=C1 SGZSRNRGHRRIKH-UHFFFAOYSA-N 0.000 description 2
- PAQTVUYYYPQYES-UHFFFAOYSA-N (2-ethyl-1-methylindol-5-yl)-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(C)C(CC)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 PAQTVUYYYPQYES-UHFFFAOYSA-N 0.000 description 2
- HBOKSYLDIPDVJY-UHFFFAOYSA-N (2-tert-butyl-1,3-benzoxazol-6-yl)-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C1=C2OC(C(C)(C)C)=NC2=CC=C1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 HBOKSYLDIPDVJY-UHFFFAOYSA-N 0.000 description 2
- YQYGGOPUTPQHAY-KIQLFZLRSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccccc1)NC(=O)C(CCCCNN[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)[C@H](C)O)C(C)C)[C@H](C)O YQYGGOPUTPQHAY-KIQLFZLRSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XKEPVKHSGXYIHB-UHFFFAOYSA-N 2-methoxy-1-[2-(4-methylphenyl)-5-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidine-1-carbonyl]-1h-indol-3-yl]ethanone Chemical compound C1=C2C(C(=O)COC)=C(C=3C=CC(C)=CC=3)NC2=CC=C1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 XKEPVKHSGXYIHB-UHFFFAOYSA-N 0.000 description 2
- BBNYCLAREVXOSG-UHFFFAOYSA-N 2-palmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CO)CO BBNYCLAREVXOSG-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000272878 Apodiformes Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- CRXUEAXEQISCEW-UHFFFAOYSA-N [1,2-bis(2-methylpropyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC(C)C)C(CC(C)C)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 CRXUEAXEQISCEW-UHFFFAOYSA-N 0.000 description 2
- FEVXZWKYBGLZEZ-UHFFFAOYSA-N [2-(3-methoxyphenyl)-1,3-benzoxazol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound COC1=CC=CC(C=2OC3=CC=C(C=C3N=2)C(=O)N2CC(C2)N2CCN(CC2)C=2N=CC=CC=2)=C1 FEVXZWKYBGLZEZ-UHFFFAOYSA-N 0.000 description 2
- BJNTVWKSUROJGQ-UHFFFAOYSA-N [2-(cyclohexylmethyl)-1h-indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2NC(CC3CCCCC3)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 BJNTVWKSUROJGQ-UHFFFAOYSA-N 0.000 description 2
- IGIMRGMJAFZMCK-UHFFFAOYSA-N [2-[(2-methoxyphenyl)methyl]-1,3-benzoxazol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound COC1=CC=CC=C1CC1=NC2=CC(C(=O)N3CC(C3)N3CCN(CC3)C=3N=CC=CC=3)=CC=C2O1 IGIMRGMJAFZMCK-UHFFFAOYSA-N 0.000 description 2
- OLZDXTCZOGRPSQ-UHFFFAOYSA-N [2-benzyl-1-(cyclohexylmethyl)indol-5-yl]-[3-[4-(2-methoxyphenyl)piperazin-1-yl]azetidin-1-yl]methanone Chemical compound COC1=CC=CC=C1N1CCN(C2CN(C2)C(=O)C=2C=C3C=C(CC=4C=CC=CC=4)N(CC4CCCCC4)C3=CC=2)CC1 OLZDXTCZOGRPSQ-UHFFFAOYSA-N 0.000 description 2
- GOGFWQDELKPPMB-UHFFFAOYSA-N [3-[4-(2-methoxyphenyl)piperazin-1-yl]azetidin-1-yl]-[1-(2-methylpropyl)-2-(phenoxymethyl)indol-5-yl]methanone Chemical compound COC1=CC=CC=C1N1CCN(C2CN(C2)C(=O)C=2C=C3C=C(COC=4C=CC=CC=4)N(CC(C)C)C3=CC=2)CC1 GOGFWQDELKPPMB-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- IEPGNWMPIFDNSD-HZJYTTRNSA-N 2-linoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(CO)CO IEPGNWMPIFDNSD-HZJYTTRNSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WKPUJZVCZXWKCK-UHFFFAOYSA-N 4-methylumbelliferyl butyate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCC)=CC=C21 WKPUJZVCZXWKCK-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010068065 Burning mouth syndrome Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 description 1
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 description 1
- 102000008906 Cannabinoid receptor type 2 Human genes 0.000 description 1
- 108050000860 Cannabinoid receptor type 2 Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010063491 Herpes zoster oticus Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000002472 Morton Neuroma Diseases 0.000 description 1
- 208000020059 Morton neuralgia Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 206010054874 Sphenopalatine neuralgia Diseases 0.000 description 1
- 208000003589 Spider Bites Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- MIOPJNTWMNEORI-OMNKOJBGSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 1
- YRWSHWBZJMEGFG-UHFFFAOYSA-N [1-(2,2-dimethylpropyl)-2-(phenoxymethyl)indol-5-yl]-[3-[4-(2-methoxyphenyl)piperazin-1-yl]azetidin-1-yl]methanone Chemical compound COC1=CC=CC=C1N1CCN(C2CN(C2)C(=O)C=2C=C3C=C(COC=4C=CC=CC=4)N(CC(C)(C)C)C3=CC=2)CC1 YRWSHWBZJMEGFG-UHFFFAOYSA-N 0.000 description 1
- KXTCIHOFWVTRIX-UHFFFAOYSA-N [1-(2,2-dimethylpropyl)-2-phenylindol-5-yl]-[3-[4-(2-methoxyphenyl)piperazin-1-yl]azetidin-1-yl]methanone Chemical compound COC1=CC=CC=C1N1CCN(C2CN(C2)C(=O)C=2C=C3C=C(N(CC(C)(C)C)C3=CC=2)C=2C=CC=CC=2)CC1 KXTCIHOFWVTRIX-UHFFFAOYSA-N 0.000 description 1
- FTCSZHHQNAULNK-UHFFFAOYSA-N [1-(2,2-dimethylpropyl)-2-phenylindol-5-yl]-[3-[4-(4-fluorophenyl)piperazin-1-yl]azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC(C)(C)C)C(C=3C=CC=CC=3)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=C(F)C=C1 FTCSZHHQNAULNK-UHFFFAOYSA-N 0.000 description 1
- GWEWKVUJHBZRBN-UHFFFAOYSA-N [2-benzyl-1-(2-methylpropyl)indol-5-yl]-[3-[4-(2-methoxyphenyl)piperazin-1-yl]azetidin-1-yl]methanone Chemical compound COC1=CC=CC=C1N1CCN(C2CN(C2)C(=O)C=2C=C3C=C(CC=4C=CC=CC=4)N(CC(C)C)C3=CC=2)CC1 GWEWKVUJHBZRBN-UHFFFAOYSA-N 0.000 description 1
- OBJAJCRBSKKDBT-UHFFFAOYSA-N [2-tert-butyl-1-(2,2-dimethylpropyl)indol-5-yl]-[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]methanone Chemical compound C=1C=C2N(CC(C)(C)C)C(C(C)(C)C)=CC2=CC=1C(=O)N(C1)CC1N(CC1)CCN1C1=CC=CC=N1 OBJAJCRBSKKDBT-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 1
- 208000004967 femoral neuropathy Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- IEPGNWMPIFDNSD-UHFFFAOYSA-N linoleic acid monoacylglycerol Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC(CO)CO IEPGNWMPIFDNSD-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000032184 meralgia paresthetica Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 201000009985 neuronitis Diseases 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229940074355 nitric acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 210000002509 periaqueductal gray Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000007771 sciatic neuropathy Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002849 thermal shift Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- HHVUFQYJOSFTEH-UHFFFAOYSA-N urb602 Chemical compound C1CCCCC1OC(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 HHVUFQYJOSFTEH-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, W and (Ia): are defined herein.
Description
HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL
AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
CROSS REFERENCE TO RELATED APPLICATIONS
This application is related to provisional application entitled, Heteroaromatic and Aromatic Piperazinyl Azetidinyl Amides as Monoacylglycerol Lipase Inhibitors, filed on April 22, 2009, United States provisional patent application serial number 61/171,660.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
FIELD OF THE INVENTION
The present invention is directed to the use of a compound of formula (I) as herein defined for the treatment, amelioration and / or prevention of an MGL
disorder in a subject, including a mammal and/or human, in which the disease, syndrome, or condition is affected by MGL.
BACKGROUND OF THE INVENTION
Cannabis sativa has been used for the treatment of pain for many years. A9-tetrahydrocannabinol is a major active ingredient from Cannabis sativa and an agonist of cannabinoid receptors (Pertwee, Brit JPharmacol, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CB1, Matsuda et al., Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2, Munro et al., Nature, 1993, 365, 61-5). CB1 is expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens, as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue and skeletal muscle (Di Marzo et al., Curr Opin Lipidol, 2007, 18, 129-140). CBz is predominantly expressed in immune cells, such as monocytes (Pacher et al., Amer JPhysiol, 2008, 294, H1133-H1134), and, under certain conditions, also in the brain (Benito et al., Brit JPharmacol, 2008, 153, 277-285) and in skeletal (Cavuoto et al., Biochem Biophys Res Commun, 2007, 364, 105-110) and cardiac (Hajrasouliha et al., Eur JPharmacol, 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid signaling through CBi/CB2 promotes analgesia in tests of acute nociception and suppresses hyperalgesia and / or allodynia in models of chronic neuropathic and inflammatory pain (Cravatt et al., JNeurobiol, 2004, 61, 149-60; Guindon et al., Brit JPharmacol, 2008, 153, 334).
Efficacy of synthetic cannabanoid receptor agonists is well documented.
Moreover, studies using cannabinoid receptor antagonists and knockout mice have also implicated the endocannabinoid system as an important modulator of nociception.
Anandamide (AEA) (Devane et al., Science, 1992, 258, 1946-9) and 2-arachidinoylglycerol (2-AG) (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90;
Sugiura et al., Biochem Biophys Res Commun, 1995, 215, 89-97) are two major endocannabinoids. AEA is hydrolyzed by fatty acid amide hydrolase (FAAH) and 2-AG is hydrolyzed by monoacylglycerol lipase (MGL) (Piomelli, Nat Rev Neurosci, 2003, 4, 873-884). Genetic ablation of FAAH elevates endogenous AEA and results in a CB1-dependent analgesia in models of acute and inflammatory pain (Lichtman et al., Pain, 2004, 109, 319-27), suggesting that the endocannabinoid system functions naturally to inhibit nociception (Cravatt et al., JNeurobiol, 2004, 61, 149-60). Unlike the constitutive increase in endocannabinoid levels using FAAH knockout mice, use of specific FAAH inhibitors transiently elevates AEA levels and results in antinociception in vivo (Kathuria et al., Nat Med, 2003, 9, 76-81). Further evidence for an endocannabinoid-mediated antinociceptive tone is demonstrated by the formation of AEA in the periaqueductal gray, a known pain center, following noxious stimulation in the periphery (Walker et al., Proc Natl Acad Sci USA, 1999, 96, 12198-203) and, conversely, by the induction of hyperalgesia following the administration of antisense RNA in the spinal cord (Dogrul et al., Pain, 2002, 100, 203-9).
With respect to 2-AG, intravenous delivery produces analgesia in the tail flick (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90) and hot plate (Lichtman et al., JPharmacol Exp Ther, 2002, 302, 73-9) assays. In contrast, it was demonstrated that 2-AG given alone is not analgesic in the hot plate assay, but when combined with other 2-monoacylglycerols (i.e., 2-linoleoyl glycerol and 2-palmitoyl glycerol), significant analgesia is attained, a phenomenon known as the "entourage effect" (Ben-Shabat et al., Eur JPharmacol, 1998, 353, 23-3 1). These "entourage" 2-monoacylglycerols are endogenous lipids that are co-released with 2-AG and potentiate endocannabinoid signaling, in part, by inhibiting 2-AG breakdown, most likely by competition for the active site on MGL. This suggests that synthetic MGL
inhibitors will have a similar effect. Indeed, URB602, a relatively weak synthetic MGL
inhibitor, showed an antinociceptive effect in a marine model of acute inflammation (Comelli et al., Brit JPharmacol, 2007, 152, 787-794).
Although the use of synthetic cannabinoid agonists have conclusively demonstrated that increased cannabinoid signaling produces analgesic and anti-inflammatory effects, it has been difficult to separate these beneficial effects from the unwanted side effects of these compounds. An alternative approach is to enhance the signaling of the endocannabinoid system by elevating the level of 2-AG, the endocannabinoid of highest abundance in the central nervous system (CNS) and gastrointestinal tract, which may be achieved by inhibition of MGL. Therefore, MGL
inhibitors are potentially useful for the treatment of pain, inflammation and CNS
disorders (Di Marzo et al., Curr Pharm Des, 2000, 6, 1361-80; Jhaveri et al., Brit J
Pharmacol, 2007, 152, 624-632; McCarberg Bill et al., Amer JTher, 2007, 14, 83), as well as glaucoma and disease states arising from elevated intraocular pressure (Njie, Ya Fatou; He, Fang; Qiao, Xhuanhong; Song, Zhoa-Hui, Exp. Eye Res., 2008, 87(2):106-14).
SUMMARY OF THE INVENTION
The present invention is directed to a method for treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by the inhibition of MGL (such as pain, the diseases that lead to such pain, inflammation and CNS
disorders) comprising, consisting of and / or consisting essentially of administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) R~ \ o ~N \N N
A
(I) selected from the group consisting of A /
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
ax A /
a compound wherein W is N, Rl is H, is Z X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
XA 5 a compound wherein W is N, Rl is H, is LL) Z , X-Y-Z is -0-C(R2)=N-, and R2 is 3-fluorophenyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
X
A
a compound wherein W is N, Rl is H, 0 is IZ% , X-Y-Z is -0-C(R2)=N-, and R2 is 4-fluorophenyl;
x A /
a compound wherein W is N, Rl is H, is 6z , X-Y-Z is -0-C(R2)=N-, and R2 is 4-methoxyphenyl;
AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
CROSS REFERENCE TO RELATED APPLICATIONS
This application is related to provisional application entitled, Heteroaromatic and Aromatic Piperazinyl Azetidinyl Amides as Monoacylglycerol Lipase Inhibitors, filed on April 22, 2009, United States provisional patent application serial number 61/171,660.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
FIELD OF THE INVENTION
The present invention is directed to the use of a compound of formula (I) as herein defined for the treatment, amelioration and / or prevention of an MGL
disorder in a subject, including a mammal and/or human, in which the disease, syndrome, or condition is affected by MGL.
BACKGROUND OF THE INVENTION
Cannabis sativa has been used for the treatment of pain for many years. A9-tetrahydrocannabinol is a major active ingredient from Cannabis sativa and an agonist of cannabinoid receptors (Pertwee, Brit JPharmacol, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CB1, Matsuda et al., Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2, Munro et al., Nature, 1993, 365, 61-5). CB1 is expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens, as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue and skeletal muscle (Di Marzo et al., Curr Opin Lipidol, 2007, 18, 129-140). CBz is predominantly expressed in immune cells, such as monocytes (Pacher et al., Amer JPhysiol, 2008, 294, H1133-H1134), and, under certain conditions, also in the brain (Benito et al., Brit JPharmacol, 2008, 153, 277-285) and in skeletal (Cavuoto et al., Biochem Biophys Res Commun, 2007, 364, 105-110) and cardiac (Hajrasouliha et al., Eur JPharmacol, 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid signaling through CBi/CB2 promotes analgesia in tests of acute nociception and suppresses hyperalgesia and / or allodynia in models of chronic neuropathic and inflammatory pain (Cravatt et al., JNeurobiol, 2004, 61, 149-60; Guindon et al., Brit JPharmacol, 2008, 153, 334).
Efficacy of synthetic cannabanoid receptor agonists is well documented.
Moreover, studies using cannabinoid receptor antagonists and knockout mice have also implicated the endocannabinoid system as an important modulator of nociception.
Anandamide (AEA) (Devane et al., Science, 1992, 258, 1946-9) and 2-arachidinoylglycerol (2-AG) (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90;
Sugiura et al., Biochem Biophys Res Commun, 1995, 215, 89-97) are two major endocannabinoids. AEA is hydrolyzed by fatty acid amide hydrolase (FAAH) and 2-AG is hydrolyzed by monoacylglycerol lipase (MGL) (Piomelli, Nat Rev Neurosci, 2003, 4, 873-884). Genetic ablation of FAAH elevates endogenous AEA and results in a CB1-dependent analgesia in models of acute and inflammatory pain (Lichtman et al., Pain, 2004, 109, 319-27), suggesting that the endocannabinoid system functions naturally to inhibit nociception (Cravatt et al., JNeurobiol, 2004, 61, 149-60). Unlike the constitutive increase in endocannabinoid levels using FAAH knockout mice, use of specific FAAH inhibitors transiently elevates AEA levels and results in antinociception in vivo (Kathuria et al., Nat Med, 2003, 9, 76-81). Further evidence for an endocannabinoid-mediated antinociceptive tone is demonstrated by the formation of AEA in the periaqueductal gray, a known pain center, following noxious stimulation in the periphery (Walker et al., Proc Natl Acad Sci USA, 1999, 96, 12198-203) and, conversely, by the induction of hyperalgesia following the administration of antisense RNA in the spinal cord (Dogrul et al., Pain, 2002, 100, 203-9).
With respect to 2-AG, intravenous delivery produces analgesia in the tail flick (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90) and hot plate (Lichtman et al., JPharmacol Exp Ther, 2002, 302, 73-9) assays. In contrast, it was demonstrated that 2-AG given alone is not analgesic in the hot plate assay, but when combined with other 2-monoacylglycerols (i.e., 2-linoleoyl glycerol and 2-palmitoyl glycerol), significant analgesia is attained, a phenomenon known as the "entourage effect" (Ben-Shabat et al., Eur JPharmacol, 1998, 353, 23-3 1). These "entourage" 2-monoacylglycerols are endogenous lipids that are co-released with 2-AG and potentiate endocannabinoid signaling, in part, by inhibiting 2-AG breakdown, most likely by competition for the active site on MGL. This suggests that synthetic MGL
inhibitors will have a similar effect. Indeed, URB602, a relatively weak synthetic MGL
inhibitor, showed an antinociceptive effect in a marine model of acute inflammation (Comelli et al., Brit JPharmacol, 2007, 152, 787-794).
Although the use of synthetic cannabinoid agonists have conclusively demonstrated that increased cannabinoid signaling produces analgesic and anti-inflammatory effects, it has been difficult to separate these beneficial effects from the unwanted side effects of these compounds. An alternative approach is to enhance the signaling of the endocannabinoid system by elevating the level of 2-AG, the endocannabinoid of highest abundance in the central nervous system (CNS) and gastrointestinal tract, which may be achieved by inhibition of MGL. Therefore, MGL
inhibitors are potentially useful for the treatment of pain, inflammation and CNS
disorders (Di Marzo et al., Curr Pharm Des, 2000, 6, 1361-80; Jhaveri et al., Brit J
Pharmacol, 2007, 152, 624-632; McCarberg Bill et al., Amer JTher, 2007, 14, 83), as well as glaucoma and disease states arising from elevated intraocular pressure (Njie, Ya Fatou; He, Fang; Qiao, Xhuanhong; Song, Zhoa-Hui, Exp. Eye Res., 2008, 87(2):106-14).
SUMMARY OF THE INVENTION
The present invention is directed to a method for treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by the inhibition of MGL (such as pain, the diseases that lead to such pain, inflammation and CNS
disorders) comprising, consisting of and / or consisting essentially of administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) R~ \ o ~N \N N
A
(I) selected from the group consisting of A /
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
ax A /
a compound wherein W is N, Rl is H, is Z X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
XA 5 a compound wherein W is N, Rl is H, is LL) Z , X-Y-Z is -0-C(R2)=N-, and R2 is 3-fluorophenyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
X
A
a compound wherein W is N, Rl is H, 0 is IZ% , X-Y-Z is -0-C(R2)=N-, and R2 is 4-fluorophenyl;
x A /
a compound wherein W is N, Rl is H, is 6z , X-Y-Z is -0-C(R2)=N-, and R2 is 4-methoxyphenyl;
A /
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is isobutyl, and R3 is isobutyl;
a X.
A
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
;Ssl~a A /
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
ax A /
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclohexylmethyl, and R3 is hydrogen;
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is isobutyl, and R3 is isobutyl;
a X.
A
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
;Ssl~a A /
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
ax A /
a compound wherein W is N, Rl is H, is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclohexylmethyl, and R3 is hydrogen;
X
0 \
a compound wherein W is N, Rl is H, is , X-Y-Z is -O-C(R2)=N-, and R2 is 2-methoxyphenylmethyl;
ax a compound wherein W is N, Rl is H, 0 is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is n-propyl, and R3 is methyl;
a compound wherein W is CH, Rl is 2-methoxy 0 is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -O-C(R2)=N-, and R2 is t-butyl;
X
A \
a compound wherein W is N, Rl is H, is , X-Y-Z is -O-C(R2)=N-, and R2 is 3-methoxyphenyl;
A ~
a compound wherein W is CH, Rl is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
0 \
a compound wherein W is N, Rl is H, is , X-Y-Z is -O-C(R2)=N-, and R2 is 2-methoxyphenylmethyl;
ax a compound wherein W is N, Rl is H, 0 is Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is n-propyl, and R3 is methyl;
a compound wherein W is CH, Rl is 2-methoxy 0 is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
A /
a compound wherein W is N, Rl is H, is \ Z , X-Y-Z is -O-C(R2)=N-, and R2 is t-butyl;
X
A \
a compound wherein W is N, Rl is H, is , X-Y-Z is -O-C(R2)=N-, and R2 is 3-methoxyphenyl;
A ~
a compound wherein W is CH, Rl is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is CH, R1 is 2-methoxy A is Z/
X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is CH, R1 is 2-methoxy 0 is az X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is CH, R1 is 2-methoxy 0 is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
A
a compound wherein W is CH, R1 is 4-fluoro, is Z X-\
Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
A /
a compound wherein W is N, R1 is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is t-butyl, and R3 is 2,2-dimethylpropyl;
X
0 \
a compound wherein W is N, R1 is H, is , X-Y-Z is -NH-C(R2)-C(R3)-, R2 is 4-methylphenyl and R3 is methoxy-methyl-carbonyl;
ax a compound wherein W is N, R1 is H, 0 is Z ,X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof.
The present invention is further directed to the use of a compound of formula (I) as herein defined, for the preparation of a medicament or pharmaceutical composition for the treatment, amelioration or prevention of a disease, syndrome, condition or disorder that is affected by the inhibition of MGL, in a subject in need thereof.
DETAILED DESCRIPTION OF THE INVENTION
In general, under standard nomenclature rules used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment. Thus, for example, a "C1-C6 alkylcarbonyl" substituent refers to a group of the formula:
O
A-C-Cl-C6 alkyl Unless otherwise noted, it is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of formula (I) can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.
The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term "therapeutically effective amount" as used herein, refers to an amount of an active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition, or disorder being treated.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in therapeutically effective amounts, as well as any product that results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
As used herein, unless otherwise noted, the terms "treating", "treatment", "ameliorating" and the like, shall include the management and care of a subject or patient (preferably mammal, more preferably human) for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, alleviate the symptoms or complications, or eliminate the disease, condition, or disorder.
As used herein, unless otherwise noted, the terms "preventing" and "prevention" shall include (a) reduction in the frequency of one or more symptoms; (b) reduction in the severity of one or more symptoms; (c) the delay or avoidance of the development of additional symptoms; and / or (d) delay or avoidance of the development of the disorder or condition.
One skilled in the art will recognize that wherein the present invention is directed to methods of prevention, a subject in need of thereof (i.e. a subject in need of prevention) shall include any subject or patient (preferably a mammal, more preferably a human) who has experienced or exhibited at least one symptom of the disorder, disease or condition to be prevented. Further, a subject in need thereof may additionally be a subject (preferably a mammal, more preferably a human) who has not exhibited any symptoms of the disorder, disease or condition to be prevented, but who has been deemed by a physician, clinician or other medical professional to be at risk of developing said disorder, disease or condition. For example, the subject may be deemed at risk of developing a disorder, disease or condition (and therefore in need of prevention or preventive treatment) as a consequence of the subject's medical history, including, but not limited to, family history, pre-disposition, co-existing (comorbid) disorders or conditions, genetic testing, and the like.
The term "MGL inhibitor" is intended to encompass a compound that interacts with MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s). The term "MGL-modulated" is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme, such as, for example, pain and the diseases that lead to such pain, inflammation and CNS disorders.
As used herein, unless otherwise noted, the term "affect" or "affected" (when referring to a disease, syndrome, condition or disorder that is affected by inhibition of MGL) shall imply a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, syndrome, condition or disorder;
and / or imply the prevention of the development of one or more symptoms or manifestations of said disease, syndrome, condition or disorder or the development of the disease, condition, syndrome or disorder.
X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is CH, R1 is 2-methoxy 0 is az X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is CH, R1 is 2-methoxy 0 is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
A
a compound wherein W is CH, R1 is 4-fluoro, is Z X-\
Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
A /
a compound wherein W is N, R1 is H, is \ Z , X-Y-Z is -CH-C(R2)-N(R3)-, R2 is t-butyl, and R3 is 2,2-dimethylpropyl;
X
0 \
a compound wherein W is N, R1 is H, is , X-Y-Z is -NH-C(R2)-C(R3)-, R2 is 4-methylphenyl and R3 is methoxy-methyl-carbonyl;
ax a compound wherein W is N, R1 is H, 0 is Z ,X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof.
The present invention is further directed to the use of a compound of formula (I) as herein defined, for the preparation of a medicament or pharmaceutical composition for the treatment, amelioration or prevention of a disease, syndrome, condition or disorder that is affected by the inhibition of MGL, in a subject in need thereof.
DETAILED DESCRIPTION OF THE INVENTION
In general, under standard nomenclature rules used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment. Thus, for example, a "C1-C6 alkylcarbonyl" substituent refers to a group of the formula:
O
A-C-Cl-C6 alkyl Unless otherwise noted, it is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of formula (I) can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.
The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term "therapeutically effective amount" as used herein, refers to an amount of an active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition, or disorder being treated.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in therapeutically effective amounts, as well as any product that results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
As used herein, unless otherwise noted, the terms "treating", "treatment", "ameliorating" and the like, shall include the management and care of a subject or patient (preferably mammal, more preferably human) for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, alleviate the symptoms or complications, or eliminate the disease, condition, or disorder.
As used herein, unless otherwise noted, the terms "preventing" and "prevention" shall include (a) reduction in the frequency of one or more symptoms; (b) reduction in the severity of one or more symptoms; (c) the delay or avoidance of the development of additional symptoms; and / or (d) delay or avoidance of the development of the disorder or condition.
One skilled in the art will recognize that wherein the present invention is directed to methods of prevention, a subject in need of thereof (i.e. a subject in need of prevention) shall include any subject or patient (preferably a mammal, more preferably a human) who has experienced or exhibited at least one symptom of the disorder, disease or condition to be prevented. Further, a subject in need thereof may additionally be a subject (preferably a mammal, more preferably a human) who has not exhibited any symptoms of the disorder, disease or condition to be prevented, but who has been deemed by a physician, clinician or other medical professional to be at risk of developing said disorder, disease or condition. For example, the subject may be deemed at risk of developing a disorder, disease or condition (and therefore in need of prevention or preventive treatment) as a consequence of the subject's medical history, including, but not limited to, family history, pre-disposition, co-existing (comorbid) disorders or conditions, genetic testing, and the like.
The term "MGL inhibitor" is intended to encompass a compound that interacts with MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s). The term "MGL-modulated" is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme, such as, for example, pain and the diseases that lead to such pain, inflammation and CNS disorders.
As used herein, unless otherwise noted, the term "affect" or "affected" (when referring to a disease, syndrome, condition or disorder that is affected by inhibition of MGL) shall imply a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, syndrome, condition or disorder;
and / or imply the prevention of the development of one or more symptoms or manifestations of said disease, syndrome, condition or disorder or the development of the disease, condition, syndrome or disorder.
The compounds of formula (I) are useful in methods for treating, ameliorating and / or preventing a disease, a syndrome, a condition or a disorder that is affected by the inhibition of MGL. Such methods comprise, consist of and/or consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment, amelioration and / or prevention, a therapeutically effective amount of a compound of formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof In particular, the compounds of formula (I) are useful for treating, ameliorating and / or preventing pain; diseases, syndromes, conditions, or disorders causing such pain; inflammation and / or CNS disorders. More particularly, the compounds of formula (I) are useful for treating, ameliorating and / or preventing inflammatory pain, inflammatory hypersensitivity conditions and / or neuropathic pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), as herein defined.
Examples of inflammatory pain include pain due to a disease, condition, syndrome, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
One type of inflammatory pain is inflammatory hyperalgesia /
hypersensitivity. Examples of inflammatory hyperalgesia include a disease, syndrome, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, urinary incontinence, benign prostatic hypertrophy, cough, asthma, rhinitis, nasal hypersensitivity, itch, contact dermititis and / or dermal allegy and chronic obstructive pulmonary disease.
In an embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing inflammatory visceral hyperalgesia in which a enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I). In a further embodiment, the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
A further embodiment of the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic pain. Examples of a neuropathic pain include pain due to a disease, syndrome, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II
(CRPS UII), radiculopathy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, postherpetic neuralgia, causalgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, trigeminal neuralgia, vulvodynia, or vidian neuralgia.
One type of neuropathic pain is neuropathic cold allodynia, which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists. Examples of neuropathic cold allodynia include allodynia due to a disease, condition, syndrome, disorder or pain state including neuropathic pain (neuralgia), pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS 1/11) and radiculopathy.
In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing CNS disorders. Examples of CNS
disorders include anxieties, such as social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress, disorder, separation anxiety disorder, and generalized anxiety disorder, as well as depression, such as major depression, bipolar disorder, seasonal affective disorder, post natal depression, manic depression, and bipolar depression.
The present invention is directed to methods of treating, ameliorating and /
or preventing a disorder, syndrome, condition or disease that is affected by the inhibition of MGL, comprising, consisting of or consisting essentially of administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) N \--/ N--ON
A
(I) selected from the group consisting of [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-lH-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin- 1-yl)-azetidin-1-yl]-methanone; (Compound #1) (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #3) (1-Isobutyl-2-p-tolyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #4) [1-Isobutyl-2-(4-methyl-benzyl)-1H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #5) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #6) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #7) (1,2-Diisobutyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #8) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #9) [1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (2-Cyclopentylmethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #12) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #13) (2-Cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #14) [2-(2-Methoxy-benzyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #15) (2-Ethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #16) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)- {3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-azetidin-1-yl}-methanone; (Compound #17) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) (2-tert-Butyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin- l -yl)-azetidin-l -yl]-methanone; (Compound #19) [2-(3-Methoxy-phenyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #20) (2-Benzyl-l-isobutyl-lH-indol-5-yl)-{3-[4-(2-methoxy-phenyl)-piperazin-l-yl]-azetidin-l-yl}-methanone; (Compound #21) [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-lH-indol-5-yl]- {3-[4-(2-methoxy-phenyl)-piperazin-l-yl]-azetidin-l-yl}-methanone; (Compound #22) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)- {3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-azetidin-l-yl}-methanone; (Compound #23) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-1 H-indol-5-yl]- {3 -[4-(2-methoxy-phenyl)-piperazin- 1-yl]-azetidin-l-yl}-methanone; (Compound #24) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]- {3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-azetidin-l-yl}-methanone; (Compound #25) [2-tert-Butyl-1-(2,2-dimethyl-propyl)-1H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #26) 2-Methoxy- 1- {5-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidine-l-carbonyl]-2-p-tolyl-lH-indol-3-yl}-ethanone; (Compound #27) (1-Cyclohexylmethyl-2-propyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #28) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof Preferably, the disease, syndrome, condition or disorder that is affected by inhibition of MGL is selected from the group consisting of pain, inflammatory pain, inflammatory hypersensitivity conditions and neuropathic pain, as herein defined.
In an embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (Ia) N \N__-CN X
W Z
(Ia) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, wherein R1, W, and -X-Y-Z- are as herein defined. In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (Ib) Ri \
-W
X
,Y
Z (m) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, wherein R1, W, and -X-Y-Z- are as herein defined. In yet another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (Ic) R N/-\N-<> 0 W Z
X "Y (Ic) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, wherein R1, W, and -X-Y-Z- are as herein defined.
In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-1 H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin- 1-yl)-azetidin-1-yl]-methanone; (Compound #1) (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #3) (1-Isobutyl-2-p-tolyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #4) [ 1-Isobutyl-2-(4-methyl-benzyl)-1H-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-l -yl)-azetidin-l-yl]-methanone; (Compound #5) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #6) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #7) (1,2-Diisobutyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #8) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #9) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (2-Cyclopentylmethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #12) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #13) (2-Cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #14) [2-(2-Methoxy-benzyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #15) (2-Ethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #16) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)- {3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-azetidin-1-yl}-methanone; (Compound #17) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to the use of a compound selected from the group consisting of [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-lH-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin- 1-yl)-azetidin-1-yl]-methanone; (Compound #1) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #3) (1-Isobutyl-2-p-tolyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #4) [ 1-Isobutyl-2-(4-methyl-benzyl)-1H-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-l -yl)-azetidin-1-yl]-methanone; (Compound #5) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin- 1-yl]-methanone; (Compound #6) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin- 1-yl]-methanone; (Compound #7) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #9) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #13) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) (1-Cyclohexylmethyl-2-propyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #28) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #3) [ 1-Isobutyl-2-(4-methyl-benzyl)-1 H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l -yl)-azetidin-1-yl]-methanone; (Compound #5) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin- 1-yl]-methanone; (Compound #7) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (2-Cyclopentylmethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #12) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1 -yl] -methanone; (Compound #13) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) [2-(3-Methoxy-phenyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- 1-yl]-methanone; (Compound #20) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-{3-[4-(2-methoxy-phenyl)-piperazin- 1-yl]-azetidin-1-yl}-methanone; (Compound #23) 2-Methoxy-1- {5-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidine-l-carbonyl]-2-p-tolyl-lH-indol-3-yl}-ethanone; (Compound #27) (1-Cyclohexylmethyl-2-propyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #28) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #3) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #6) (2-tert-Butyl-benzooxazol-6-yl)-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l -yl]-methanone; (Compound #19) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to the use of any single compound or subset of compounds selected from the compounds listed in Tables 1-below, or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, for the treatment, amelioration or prevention or a disease, syndrome, condition or disorder that is affected by the inhibition of MGL, in a subject in need thereof. The compounds of formula (I) of the present invention are as listed in Tables 1-3, below.
Table 1: Compounds of Formula (Ia) R
__-ON 0 X Y
N N
W Z
Cmpd No. W Rl X-Y-Z R2 3 N H -O-C(R2)=N- 3-fluorophenyl 6 N H -O-C(R2)=N- 4-fluorophenyl 7 N H -O-C(R2)=N- 4-methoxyphenyl Table 2: Compounds of Formula (Ib) \
N N N
W X
Z l__Y
Cmpd No. W Rl X-Y-Z R2 R3 -CH-C(R2)- 2,2-1 N H N(R3)- phenoxymethyl dimethylpropyl 2 N H -O-C(R2)=N- cyclohexyl -CH-C(R2)-4 N H N(R3)- 4-methylphenyl isobutyl -CH-C(R2)-N H N(R3)- phenylmethyl isobutyl -CH-C(R2)-8 N H N(R3)- isobutyl isobutyl -CH-C(R2)-9 N H N(R3)- phenoxymethyl isobutyl -CH-C(R2)- 2,2-N H N(R3)- phenyl dimethylpropyl -CH-C(R2)- cyclohexyl-11 N H N(R3)- phenoxymethyl methyl -CH-C(R2)- cyclopentyl-12 N H N(R3)- methyl methyl -CH-C(R2)-13 N H N(R3)- phenyl isobutyl -CH-C(R2)- cyclohexy-14 N H N(R3)- lmethyl hydrogen -CH-C(R2)-16 N H N(R3)- n-propyl methyl -CH-C(R2)-17 CH 2-methoxy N(R3)- phenoxymethyl isobutyl -CH-C(R2)- cyclohexyl-18 N H N(R3)- phenylmethyl methyl 19 N H -O-C(R2)=N- t-butyl -CH-C(R2)-21 CH 2-methoxy N(R3)- phenylmethyl isobutyl -CH-C(R2)- 2,2-dimethyl-22 CH 2-methoxy N(R3)- phenoxymethyl propyl -CH-C(R2)- cyclohexyl-23 CH 2-methoxy N(R3)- phenylmethyl methyl -CH-C(R2)- 2,2-dimethyl-24 CH 2-methoxy N(R3)- phenyl propyl -CH-C(R2)- 2,2-dimethyl-25 CH 4-fluoro N(R3)- phenyl propyl -CH-C(R2)- 2,2-26 N H N(R3)- t-butyl dimethypropyl -CH-C(R2)- cyclohexyl-28 N H N(R3)- n-propyl methyl Table 3: Compounds of Formula (Ic) \
N N N
W Z
X "-Y
Cmpd No. W R1 X-Y-Z R2 R3 2-methoxy-15 N H -O-C(R2)=N- phenylmethyl 3-methoxy-20 N H -O-C(R2)=N- phenyl -NH-C(R2)- methoxy-27 N H C(R3)- 4-methylphenyl methyl-carbonyl In an embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is selected from the group consisting of inflammatory pain and neuropathic pain; comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) N N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In an embodiment, the present invention is directed to treating, ameliorating or preventing inflammatory pain; comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) O
R ~ \ N \N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In another embodiment of the present invention, the inflammatory pain is selected from the group consisting of visceral pain and inflammatory hyeralgesia, preferably visceral pain.
In an embodiment, the present invention is directed to treating, ameliorating or preventing inflammatory hyperalgesia, comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) O
R ~ \ N \N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In another embodiment of the present invention, the inflammatory hyperalgesia is ulcerative colitis.
In an embodiment, the present invention is directed to treating, ameliorating or preventing neuropathic pain, comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) O
R ~ \ N \N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In another embodiment of the present invention, the neuropathic pain is neuropathic cold allodynia.
For use in medicine, salts of compounds of formula (I) refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of compounds of formula (I) or of their pharmaceutically acceptable salts thereof Suitable pharmaceutically acceptable salts of compounds of formula (I) include acid addition salts which can, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
Furthermore, where the compounds of formula (I) carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; and salts formed with suitable organic ligands, such as quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate.
Representative acids and bases that may be used in the preparation of pharmaceutically acceptable salts include acids such as acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, a-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, ( )-DL-lactic acid, lactobionic acid, maleic acid, (-)-L-malic acid, malonic acid, ( )-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebaic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid; and bases including ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide.
Embodiments of the present invention include prodrugs of compounds of formula (I). In general, such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound. Thus, in the methods of treating or preventing embodiments of the present invention, the term "administering" encompasses the treatment or prevention of the various diseases, conditions, syndromes and disorders described with the compound specifically disclosed or with a compound that may not be specifically disclosed, but which converts to the specified compound in vivo after administration to a patient.
Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H.
Bundgaard, Elsevier, 1985.
Where the compounds according to embodiments of this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. The skilled artisan will understand that the term compound as used herein, is meant to include solvated compounds of Formula (I).
Where the processes for the preparation of the compounds according to certain embodiments of the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography.
The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
One embodiment of the present invention is directed to a composition, including a pharmaceutical composition, comprising, consisting of, and/or consisting essentially of the (+)-enantiomer of a compound of formula (I) wherein said composition is substantially free from the (-)-isomer of said compound. In the present context, substantially free means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (-)-isomer calculated as % (+) -enantiomer = (mass (+) - enantiomer) X100 (mass (+) - enantiomer) + (mass(-) - enantiomer) Another embodiment of the present invention is a composition, including a pharmaceutical composition, comprising, consisting of, and consisting essentially of the (-)-enantiomer of a compound of formula (I) wherein said composition is substantially free from the (+)-isomer of said compound. In the present context, substantially free from means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (+)-isomer calculated as % (-) - enantiomer = (mass (-) - enantiomer) x 100 (mass (+) - enantiomer) + (mass(-) - enantiomer) During any of the processes for preparation of the compounds of the various embodiments of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, Second Edition, J.F.W. McOmie, Plenum Press, 1973;
T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley &
Sons, 1991; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Even though the compounds of embodiments of the present invention (including their pharmaceutically acceptable salts and pharmaceutically acceptable solvates) can be administered alone, they will generally be administered in admixture with a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient and/or a pharmaceutically acceptable diluent selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. Thus, particular embodiments of the present invention are directed to pharmaceutical and veterinary compositions comprising compounds of formula (I) and at least one pharmaceutically acceptable carrier, pharmaceutically acceptable excipient, and/or pharmaceutically acceptable diluent.
By way of example, in the pharmaceutical compositions of embodiments of the present invention, the compounds of formula (I) may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s), and combinations thereof Solid oral dosage forms, such as tablets or capsules, containing the compounds of the present invention may be administered in at least one dosage form at a time, as appropriate. It is also possible to administer the compounds in sustained release formulations.
Additional oral forms in which the present inventive compounds may be administered include elixirs, solutions, syrups, and suspensions; each optionally containing flavoring agents and coloring agents.
Alternatively, compounds of formula (I) can be administered by inhalation (intratracheal or intranasal) or in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder.
For example, they can be incorporated into a cream comprising, consisting of, and/or consisting essentially of an aqueous emulsion of polyethylene glycols or liquid paraffin.
They can also be incorporated, at a concentration of between about 1 % and about 10 %
by weight of the cream, into an ointment comprising, consisting of, and/or consisting essentially of a white wax or white soft paraffin base together with any stabilizers and preservatives as may be required. An alternative means of administration includes transdermal administration by using a skin or transdermal patch.
The pharmaceutical compositions of the present invention (as well as the compounds of the present invention alone) can also be injected parenterally, for example intracavernosally, intravenously, intramuscularly, subcutaneously, intradermally or intrathecally. In this case, the compositions will also include at least one of a suitable carrier, a suitable excipient, and a suitable diluent.
For parenteral administration, the pharmaceutical compositions of the present invention are best used in the form of a sterile aqueous solution that may contain other substances, for example, enough salts and monosaccharides to make the solution isotonic with blood.
For buccal or sublingual administration, the pharmaceutical compositions of the present invention may be administered in the form of tablets or lozenges, which can be formulated in a conventional manner.
By way of further example, pharmaceutical compositions containing at least one of the compounds of formula (I) can be prepared by mixing the compound(s) with a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, and/or a pharmaceutically acceptable excipient according to conventional pharmaceutical compounding techniques. The carrier, excipient, and diluent may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral, etc.).
Thus for liquid oral preparations, such as suspensions, syrups, elixirs and solutions, suitable carriers, excipients and diluents include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and tablets, suitable carriers, excipients and diluents include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations also may be optionally coated with substances, such as, sugars, or be enterically -coated so as to modulate the major site of absorption and disintegration. For parenteral administration, the carrier, excipient and diluent will usually include sterile water, and other ingredients may be added to increase solubility and preservation of the composition. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives, such as solubilizers and preservatives.
A therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition thereof includes a dose range from about 0.1 mg to about 3000 mg, or any amount or range therein, in particular from about 1 mg to about 1000 mg, or any amount or range therein, more particularly, from about 10 mg to about 500 mg, or any amount or range therein, of ingredient compound of formula (I) in a regimen of about 1 to 4 times per day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for a compound of formula (I) will vary as will the diseases, syndromes, conditions, and disorders being treated.
For oral administration, a pharmaceutical composition is preferably provided in the form of tablets containing about 0.01, about 10, about 50, about 100, about 150, about 200, about 250, and about 500 milligrams of a compound of formula (I).
Advantageously, a compound of formula (I) may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three and four times daily.
Optimal dosages of a compound of formula (I) to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease, syndrome, condition, or disorder. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to achieve an appropriate therapeutic level and desired therapeutic effect. The above dosages are thus exemplary of the average case.
There can be, of course, individual instances wherein higher or lower dosage ranges are merited, and such are within the scope of this invention.
One skilled in the art will recognize that, both in vivo and in vitro trials using suitable, known and generally accepted cell and / or animal models are predictive of the ability of a test compound to treat or prevent a given disorder. One skilled in the art will further recognize that human clinical trails including first-in-human, dose ranging and efficacy trials, in healthy patients and / or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.
A compound of formula (I) may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of a compound of formula (I) is required for a subject in need thereof.
GENERAL SYNTHETIC METHODS
Representative compounds of the present invention may be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the specific chemical reactions and specific conditions described in the schemes and examples. The various starting materials used in the schemes are commercially available or may be prepared by methods well within the skill of persons versed in the art. The variables are as defined herein and within the skill of persons versed in the art.
Abbreviations used in the specification, particularly the Schemes and Examples, are as follows:
DCC = N,N-Dicyclohexylcarbodiimide DCM = Dichloromethane DIPEA or DIEA = Diisopropylethylamine DMF = N,N-Dimethylformamide DMSO = Dimethylsulfoxide EDTA = Ethylenediaminetetraacetic acid EtOAc = Ethyl Acetate HATU = O-(7-Azabenzotriazol-1-yl)-N,N,N",N"-Tetramethyl Uronium Hexafluorophosphate HBTU = O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate HEPES = 4-(2-Hydroxyethyl)-1-piperazineethane sulfonic acid TEA = Triethylamine TFA = Trifluoroacetic Acid THE = Tetrahydrofuran The compounds of Formula (I) of the present invention may be prepared according to the process as outlined in Scheme 1, below.
R H3CO3S --ON-PG1 '~-\ N NH
\ I
W (VI) (V) \N N-PG1 N N NH
\C\-N W W
(VII) (VIII) Z N \N N
\~ X
(IX) I ~Y
(I) / Z
Scheme 1 Accordingly, a suitably substituted compound of formula (V), a known compound or compound prepared by known methods, is reacted with a suitably substituted compound of formula (VI), wherein PG1 is a suitably selected nitrogen protecting group such as -CH(phenyl)2, benzyl, t-butyl, methyl, and the like, preferably -CH(phenyl)2, a known compound or compound prepared by known methods; in the presence of an organic base such as DIPEA, pyridine, and the like (preferably not TEA); in an organic solvent such as acetonitrile, THF, DCM, and the like;
preferably at a temperature in the range of from about 50 C to about 90 C; to yield the corresponding compound of formula (VII).
The compound of formula (VII) is de-protected according to known methods, to yield the corresponding compound of formula (VIII). For example, wherein PG1 is -CH(phenyl)2, the compound of formula (VII) is de-protected by reacting with 1-chloroethyl chloroformate, in an organic solvent such as dichloromethane, and then refluxed in an organic solvent such as methanol, to yield the corresponding compound of formula (VIII).
The compound of formula (VIII) is reacted with a suitably substituted compound of formula (IX), wherein LG1 is selected from the group consisting of -C(O)Cl and C(O)OH, and wherein LG1 is bound at the desired bonding position on benzene ring of the the benzo-fused portion of the compound of formula (IX), a known compound or compound prepared by known methods, in the presence of a suitably selected coupling agent such as HATU, HBTU, DCC, and the like; in the presence of a suitably selected organic base such as DIPEA, TEA, pyridine, and the like; in an organic solvent such as acetonitrile, DMF, DCM, and the like; to yield the corresponding compound of formula (I).
The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.
In the Examples which follow, some synthesis products are listed as having been isolated as a residue. It will be understood by one of ordinary skill in the art that the term "residue" does not limit the physical state in which the product was isolated and may include, for example, a solid, an oil, a foam, a gum, a syrup, and the like.
Example 1: (2-Cyclohexyl-benzooxazol-6-yl)-f3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yll-methanone O
O
N / N
NJ
STEP A: 2-Cyclohexyl-benzooxazole-6-carboxylic acid To a solution of 4-amino-3-hydroxy-benzoic acid methyl ester (5 g, 29.91 mmol) in CH3OH (150 mL) was added cyclohexanecarbaldehyde (3.6 mL, 29.91 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h. The solvent was removed by evaporation and CH3CN (150 mL) was added to the residue. Lead (IV) acetate (13.26 g, 29.91 mmol) was added as one portion under N2 and the resulting mixture was refluxed for 10 min. After cooling, the resulting solid was filtered and washed with CH3CN. To the filtrate was then added 3N NaOH (40 mL). The resulting mixture was stirred at 50 C for 18 h. The solvent was removed by evaporation and the resulting residue was purified by flash chromatography on silica gel to yield 2-cyclohexyl-benzooxazole-6-carboxylic acid. MS m/z (M+H+) 246.2.
STEP B: (2-Cyclohexyl-benzooxazol-6-yl)-(3-hey-azetidin-1-yl)-methanone To a solution of 2-cyclohexyl-benzooxazole-6-carboxylic acid (0.47 g, 1.9 mmol) and HBTU (0.94 g, 2.5 mmol) in DMF (10 mL) was added DIPEA (1.4 mL, 7.6 mmol). The resulting mixture was stirred at room temperature for 10 min, and then the hydrochloride salt of azetidin-3-ol (0.452 g, 4.7 mmol) was added. The resulting mixture was stirred at room temperature for 1 h, and then purified by reverse phase liquid chromatography. Fractions containing product were lyophilized to yield (2-cyclohexyl-benzooxazol-6-yl)-(3-hydroxy-azetidin-1-yl)-methanone. MS m/z (M+H+) 301.
STEP C: 2-Cyclohex. {[3-(4-pyridin-2-yllpiperazin-1-yl)azetidin-1-yl]carbony}-1,3-benzoxazole Methanesulfonyl chloride (0.152 mL, 1.9 mmol) was added dropwise to a solution of (2-cyclohexyl-benzooxazol-6-yl)-(3-hydroxy-azetidin-1-yl)-methanone (0.48 g, 1.6 mmol) and DIPEA (0.558 mL, 3.2 mmol) in DCM (20 mL) at -40 C
under nitrogen. Immediately following the addition, the cooling bath was removed and the mixture slowly warmed to room temperature. The resulting mixture was then washed with water, dried using magnesium sulfate, filtered, and the solvent removed under reduced pressure. The resulting residue was dissolved in acetonitrile (1 mL).
DIPEA
(0.41 mL, 2.4 mmol) and N-(2-pyridyl)piperazine (1.6 mmol) were added. The resulting mixture was then microwaved at 160 C for 4 hours. DMF (3 mL) was added to the resulting mixture, which was then purified by reverse phase liquid chromatography. The fractions containing product were diluted with IN HCl (5 mL) and then lyophilized to yield 2-cyclohexyl-6-{[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]carbonyl}-1,3-benzoxazole as its corresponding hydrochloride salt.
1H NMR (400MHz, DMSO-d6) 6= 9.21 (s, 1 H), 8.15 (d, J= 5.1 Hz, 1 H), 7.96 (d, J= 8.3 Hz, 1 H), 7.81 (br. s., 1 H), 7.16 - 7.22 (m, 1 H), 7.06 (d, J= 8.3 Hz, 1 H), 6.88 (s, 1 H), 4.54 (br. s., 2 H), 4.38 (d, J= 6.6 Hz, 2 H), 4.13 (br. s., 1 H), 3.73 (br. s., 8 H), 3.31 - 3.60 (m, 1 H), 1.77 (d, J= 13.7 Hz, 4 H), 1.65 (br. s., 1 H), 1.32 - 1.44 (m, 2 H), 1.15 - 1.32 (m, 2 H), 1.06 (t, J= 7.0 Hz, 1 H). MS m/z (M+H+) 446.
Compounds #2 through 28 may be similarly prepared according to the procedures as described in Example 1, above and substituting suitably selected and / or substituted reagents, starting materials and purification methods known to those skilled in the art.
Example 2: (in vitro Assay): MGL Enzyme Activity Assay All rate-based assays were performed in black 384-well polypropylene PCR
microplates (Abgene) in a total volume of 30 L. Substrate 4-methylumbelliferyl butyrate (4MU-B, Sigma) and purified mutant MGL enzyme (mut-MGLL 11-313 L179S L186S) were diluted separately into 20 mM PIPES buffer (pH 7), containing 150 mM NaCl, and 0.001% Tween 20. Compounds of Formula (I) were pre-dispensed (50 nL) into the assay plate using a Cartisian Hummingbird (Genomic Solutions, Ann Arbor, MI) prior to adding 4MU-B (25 pL of 1.2X solution, final concentration of 10 M) followed by enzyme (5 pL of a 6X solution, final concentration of 5 nM) to initiate the reaction. Final compound concentrations ranged from 17 to 0.0003 M.
The fluorescence change due to 4MU-B cleavage was monitored with excitation and emission wavelengths of 335 and 440 nm, respectively, and a bandwidth of 10 nm (Safire2, Tecan) at 37 C for 5 min.
The IC50 values for compounds of Formula (I) were determined using Excel from a fit of the equation to the concentration- response-plot of the fractional activity as a function of inhibitor concentration.
Example 3: (in vitro Assay): MGL ThermoFluor Assay The ThermoFluor (TF) assay is a 384-well plate-based binding assay that measures thermal stability of proteins (Pantoliano, M. W., Petrella, E. C., Kwasnoski, J.
D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B.
A., Lane, P., and Salemme, F. R. JBiomol Screen 2001, 6, 429-40; Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. Biochemistry 2005, 44, 5258-66). The experiments were carried out using instruments available from Johnson & Johnson Pharmaceutical Research & Development, LLC. TF dye used in all experiments was 1,8-ANS
(Invitrogen: A-47). Final TF assay conditions used for MGL studies were 0.07 mg/ml of purified mutant MGL (mut-MGLL 11-313 L179S L186S), 100 M ANS, 200 mM
NaCl, 0.001% Tween-20 in 50 mM PIPES (pH = 7.0).
Screening compound plates contained 100% DMSO compound solutions at a single concentration. For follow-up concentration-response studies, compounds were arranged in a pre-dispensed plate (Greiner Bio-one: 781280), wherein compounds were serially diluted in 100% DMSO across 11 columns within a series. Columns 12 and 24 were used as DMSO reference and contained no compound. For both single and multiple compound concentration-response experiments, the compound aliquots (50 nL) were robotically pre-dispensed directly into black 384-well polypropylene PCR
microplates (Abgene: TF-03 84/k) using the Cartesian Hummingbird liquid handler (Genomic Solutions, Ann Arbor, MI). . Following compound dispense, protein and dye solutions were added to achieve the final assay volume of 3 L. The assay solutions were overlayed with 1 pL of silicone oil (Fluka, type DC 200: 85411) to prevent evaporation.
Bar-coded assay plates were robotically loaded onto a thermostatically controlled PCR-type thermal block and then heated from 40 to 90 C degrees at a ramp-rate of 1 C/min for all experiments. Fluorescence was measured by continuous illumination with UV light (Hamamatsu LC6) supplied via fiber optics and filtered through a band-pass filter (380-400 nm; > 6 OD cutoff). Fluorescence emission of the entire 384-well plate was detected by measuring light intensity using a CCD
camera (Sensys, Roper Scientific) filtered to detect 500 25 nm, resulting in simultaneous and independent readings of all 384 wells. A single image with 20-sec exposure time was collected at each temperature, and the sum of the pixel intensity in a given area of the assay plate was recorded versus temperature and fit to standard equations to yield the Tm. (Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R., JBiomol Screen 2001, 6, 429-40).
Example 4: 2-AG Accumulation assay HeLa cells were homogenated with a Polytron in 10 ml (about 400 million cells) HEPES buffer (HEPES 20 mM, pH 7.4, NaCl 125 mM, EDTA 1 mM, KC15 mM, Glucose 20 mM). The homogenate from 20 million cells (0.5 ml) was incubated with MGL inhibitor for 15 min to block MGL activity and then the HEPES buffer solution was incubated with calcium (10 mM) for 20 min. The total reaction volume was 5 ml. The reactions were stopped by 6 mL organic solvent extraction (2:1 chloroform/methanol). Methoxy arachidonyl fluorophosphonate (MAFP) was used as positive control. In the absence of MAFP the 2-AG levels are about 3.4 pmol/sample.
In the presence of 100 nM MAFP 2-AG levels increase to 174 pmol/sample.
Accumulated 2-AG in the organic phase was measured by a HPLC/MS method, according to the following equation: %MAFP = (Compound 2-AG/MAFP 2-AG) x 100.
Representative compounds of formula (I) were tested according to the procedure as described in Example 2, 3 and 4 above, with results as listed in Table 4.
Table 4 Example 4 Example 4 Example 2 Example 3 % MAFP @ % MAFP @
Cmpd No. IC50 ( M) Kd ( M) 1 M 10 M
1 0.031 0.001 2 0.050 0.130 39.7 87.6 3 0.055 0.091 45.7 82.9 4 0.060 0.002 0.077 0.008 82.9 6 0.100 0.048 30.6 68.8 7 0.186 0.083 79.5 8 0.220 0.330 72.9 9 0.230 0.040 67.8 0.330 0.020 160.1 11 0.350 0.010 160.1 12 0.360 5.000 142.0 13 0.430 0.030 93.5 14 0.440 5.000 53.7 0.470 1.850 57.6 16 0.810 4.550 61.1 17 0.880 4.000 25.9 18 0.920 0.050 134.6 19 1.073 0.172 19.9 47.3 1.340 5.560 86.9 21 1.420 6.670 29.2 22 1.670 5.560 50.1 23 1.890 2.500 84.5 24 1.980 5.000 58.8 3.810 6.670 65.8 26 5.460 11.110 37.0 27 9.441 28.569 76.3 28 0.090 77.0 Example 5: Oral Formulation - Prophetic Example As a specific embodiment of an oral composition, 100 mg of the compound #1, prepared as in Example 1 is formulated with sufficient finely divided lactose to provide 5 a total amount of 580 to 590 mg to fill a size 0 hard gel capsule.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.
Examples of inflammatory pain include pain due to a disease, condition, syndrome, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
One type of inflammatory pain is inflammatory hyperalgesia /
hypersensitivity. Examples of inflammatory hyperalgesia include a disease, syndrome, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, urinary incontinence, benign prostatic hypertrophy, cough, asthma, rhinitis, nasal hypersensitivity, itch, contact dermititis and / or dermal allegy and chronic obstructive pulmonary disease.
In an embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing inflammatory visceral hyperalgesia in which a enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I). In a further embodiment, the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
A further embodiment of the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic pain. Examples of a neuropathic pain include pain due to a disease, syndrome, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II
(CRPS UII), radiculopathy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, postherpetic neuralgia, causalgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, trigeminal neuralgia, vulvodynia, or vidian neuralgia.
One type of neuropathic pain is neuropathic cold allodynia, which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists. Examples of neuropathic cold allodynia include allodynia due to a disease, condition, syndrome, disorder or pain state including neuropathic pain (neuralgia), pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS 1/11) and radiculopathy.
In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing CNS disorders. Examples of CNS
disorders include anxieties, such as social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress, disorder, separation anxiety disorder, and generalized anxiety disorder, as well as depression, such as major depression, bipolar disorder, seasonal affective disorder, post natal depression, manic depression, and bipolar depression.
The present invention is directed to methods of treating, ameliorating and /
or preventing a disorder, syndrome, condition or disease that is affected by the inhibition of MGL, comprising, consisting of or consisting essentially of administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) N \--/ N--ON
A
(I) selected from the group consisting of [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-lH-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin- 1-yl)-azetidin-1-yl]-methanone; (Compound #1) (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #3) (1-Isobutyl-2-p-tolyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #4) [1-Isobutyl-2-(4-methyl-benzyl)-1H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #5) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #6) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #7) (1,2-Diisobutyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #8) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #9) [1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (2-Cyclopentylmethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #12) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #13) (2-Cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #14) [2-(2-Methoxy-benzyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #15) (2-Ethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #16) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)- {3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-azetidin-1-yl}-methanone; (Compound #17) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) (2-tert-Butyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin- l -yl)-azetidin-l -yl]-methanone; (Compound #19) [2-(3-Methoxy-phenyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #20) (2-Benzyl-l-isobutyl-lH-indol-5-yl)-{3-[4-(2-methoxy-phenyl)-piperazin-l-yl]-azetidin-l-yl}-methanone; (Compound #21) [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-lH-indol-5-yl]- {3-[4-(2-methoxy-phenyl)-piperazin-l-yl]-azetidin-l-yl}-methanone; (Compound #22) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)- {3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-azetidin-l-yl}-methanone; (Compound #23) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-1 H-indol-5-yl]- {3 -[4-(2-methoxy-phenyl)-piperazin- 1-yl]-azetidin-l-yl}-methanone; (Compound #24) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]- {3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-azetidin-l-yl}-methanone; (Compound #25) [2-tert-Butyl-1-(2,2-dimethyl-propyl)-1H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #26) 2-Methoxy- 1- {5-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidine-l-carbonyl]-2-p-tolyl-lH-indol-3-yl}-ethanone; (Compound #27) (1-Cyclohexylmethyl-2-propyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #28) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof Preferably, the disease, syndrome, condition or disorder that is affected by inhibition of MGL is selected from the group consisting of pain, inflammatory pain, inflammatory hypersensitivity conditions and neuropathic pain, as herein defined.
In an embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (Ia) N \N__-CN X
W Z
(Ia) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, wherein R1, W, and -X-Y-Z- are as herein defined. In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (Ib) Ri \
-W
X
,Y
Z (m) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, wherein R1, W, and -X-Y-Z- are as herein defined. In yet another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (Ic) R N/-\N-<> 0 W Z
X "Y (Ic) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, wherein R1, W, and -X-Y-Z- are as herein defined.
In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-1 H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin- 1-yl)-azetidin-1-yl]-methanone; (Compound #1) (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #3) (1-Isobutyl-2-p-tolyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #4) [ 1-Isobutyl-2-(4-methyl-benzyl)-1H-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-l -yl)-azetidin-l-yl]-methanone; (Compound #5) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #6) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #7) (1,2-Diisobutyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #8) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- l-yl]-methanone; (Compound #9) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (2-Cyclopentylmethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #12) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #13) (2-Cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #14) [2-(2-Methoxy-benzyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #15) (2-Ethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #16) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)- {3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-azetidin-1-yl}-methanone; (Compound #17) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to the use of a compound selected from the group consisting of [ 1-(2,2-Dimethyl-propyl)-2-phenoxymethyl-lH-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin- 1-yl)-azetidin-1-yl]-methanone; (Compound #1) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #3) (1-Isobutyl-2-p-tolyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #4) [ 1-Isobutyl-2-(4-methyl-benzyl)-1H-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-l -yl)-azetidin-1-yl]-methanone; (Compound #5) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin- 1-yl]-methanone; (Compound #6) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin- 1-yl]-methanone; (Compound #7) (1-Isobutyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #9) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #13) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) (1-Cyclohexylmethyl-2-propyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1-yl]-methanone; (Compound #28) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #3) [ 1-Isobutyl-2-(4-methyl-benzyl)-1 H-indol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l -yl)-azetidin-1-yl]-methanone; (Compound #5) [2-(4-Methoxy-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin- 1-yl]-methanone; (Compound #7) [ 1-(2,2-Dimethyl-propyl)-2-phenyl-lH-indol-5-yl]-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #10) (1-Cyclohexylmethyl-2-phenoxymethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #11) (2-Cyclopentylmethyl-l-methyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #12) (1-Isobutyl-2-phenyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-1 -yl] -methanone; (Compound #13) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #18) [2-(3-Methoxy-phenyl)-benzooxazol-5-yl]-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin- 1-yl]-methanone; (Compound #20) (2-Benzyl-l-cyclohexylmethyl-lH-indol-5-yl)-{3-[4-(2-methoxy-phenyl)-piperazin- 1-yl]-azetidin-1-yl}-methanone; (Compound #23) 2-Methoxy-1- {5-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidine-l-carbonyl]-2-p-tolyl-lH-indol-3-yl}-ethanone; (Compound #27) (1-Cyclohexylmethyl-2-propyl-lH-indol-5-yl)-[3-(4-pyridin-2-yl-piperazin-l-yl)-azetidin-l-yl]-methanone; (Compound #28) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of (2-Cyclohexyl-benzooxazol-6-yl)-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l-yl]-methanone; (Compound #2) [2-(3-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #3) [2-(4-Fluoro-phenyl)-benzooxazol-7-yl]-[3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yl]-methanone; (Compound #6) (2-tert-Butyl-benzooxazol-6-yl)-[3 -(4-pyridin-2-yl-piperazin-1-yl)-azetidin-l -yl]-methanone; (Compound #19) and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof.
In another embodiment, the present invention is directed to the use of any single compound or subset of compounds selected from the compounds listed in Tables 1-below, or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof, for the treatment, amelioration or prevention or a disease, syndrome, condition or disorder that is affected by the inhibition of MGL, in a subject in need thereof. The compounds of formula (I) of the present invention are as listed in Tables 1-3, below.
Table 1: Compounds of Formula (Ia) R
__-ON 0 X Y
N N
W Z
Cmpd No. W Rl X-Y-Z R2 3 N H -O-C(R2)=N- 3-fluorophenyl 6 N H -O-C(R2)=N- 4-fluorophenyl 7 N H -O-C(R2)=N- 4-methoxyphenyl Table 2: Compounds of Formula (Ib) \
N N N
W X
Z l__Y
Cmpd No. W Rl X-Y-Z R2 R3 -CH-C(R2)- 2,2-1 N H N(R3)- phenoxymethyl dimethylpropyl 2 N H -O-C(R2)=N- cyclohexyl -CH-C(R2)-4 N H N(R3)- 4-methylphenyl isobutyl -CH-C(R2)-N H N(R3)- phenylmethyl isobutyl -CH-C(R2)-8 N H N(R3)- isobutyl isobutyl -CH-C(R2)-9 N H N(R3)- phenoxymethyl isobutyl -CH-C(R2)- 2,2-N H N(R3)- phenyl dimethylpropyl -CH-C(R2)- cyclohexyl-11 N H N(R3)- phenoxymethyl methyl -CH-C(R2)- cyclopentyl-12 N H N(R3)- methyl methyl -CH-C(R2)-13 N H N(R3)- phenyl isobutyl -CH-C(R2)- cyclohexy-14 N H N(R3)- lmethyl hydrogen -CH-C(R2)-16 N H N(R3)- n-propyl methyl -CH-C(R2)-17 CH 2-methoxy N(R3)- phenoxymethyl isobutyl -CH-C(R2)- cyclohexyl-18 N H N(R3)- phenylmethyl methyl 19 N H -O-C(R2)=N- t-butyl -CH-C(R2)-21 CH 2-methoxy N(R3)- phenylmethyl isobutyl -CH-C(R2)- 2,2-dimethyl-22 CH 2-methoxy N(R3)- phenoxymethyl propyl -CH-C(R2)- cyclohexyl-23 CH 2-methoxy N(R3)- phenylmethyl methyl -CH-C(R2)- 2,2-dimethyl-24 CH 2-methoxy N(R3)- phenyl propyl -CH-C(R2)- 2,2-dimethyl-25 CH 4-fluoro N(R3)- phenyl propyl -CH-C(R2)- 2,2-26 N H N(R3)- t-butyl dimethypropyl -CH-C(R2)- cyclohexyl-28 N H N(R3)- n-propyl methyl Table 3: Compounds of Formula (Ic) \
N N N
W Z
X "-Y
Cmpd No. W R1 X-Y-Z R2 R3 2-methoxy-15 N H -O-C(R2)=N- phenylmethyl 3-methoxy-20 N H -O-C(R2)=N- phenyl -NH-C(R2)- methoxy-27 N H C(R3)- 4-methylphenyl methyl-carbonyl In an embodiment, the present invention is directed to treating, ameliorating or preventing a disease, syndrome, condition or disorder that is affected by inhibition of MGL, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is selected from the group consisting of inflammatory pain and neuropathic pain; comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) N N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In an embodiment, the present invention is directed to treating, ameliorating or preventing inflammatory pain; comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) O
R ~ \ N \N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In another embodiment of the present invention, the inflammatory pain is selected from the group consisting of visceral pain and inflammatory hyeralgesia, preferably visceral pain.
In an embodiment, the present invention is directed to treating, ameliorating or preventing inflammatory hyperalgesia, comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) O
R ~ \ N \N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In another embodiment of the present invention, the inflammatory hyperalgesia is ulcerative colitis.
In an embodiment, the present invention is directed to treating, ameliorating or preventing neuropathic pain, comprising administering to a subject in need thereof (including a mammal and / or human), a therapeutically effective amount of a compound of formula (I) O
R ~ \ N \N N
A
(I) selected from the group as herein defined; and enantiomers, diastereomers, solvates and pharmaceutically acceptable salt thereof In another embodiment of the present invention, the neuropathic pain is neuropathic cold allodynia.
For use in medicine, salts of compounds of formula (I) refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of compounds of formula (I) or of their pharmaceutically acceptable salts thereof Suitable pharmaceutically acceptable salts of compounds of formula (I) include acid addition salts which can, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
Furthermore, where the compounds of formula (I) carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; and salts formed with suitable organic ligands, such as quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate.
Representative acids and bases that may be used in the preparation of pharmaceutically acceptable salts include acids such as acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, a-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, ( )-DL-lactic acid, lactobionic acid, maleic acid, (-)-L-malic acid, malonic acid, ( )-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebaic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid; and bases including ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide.
Embodiments of the present invention include prodrugs of compounds of formula (I). In general, such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound. Thus, in the methods of treating or preventing embodiments of the present invention, the term "administering" encompasses the treatment or prevention of the various diseases, conditions, syndromes and disorders described with the compound specifically disclosed or with a compound that may not be specifically disclosed, but which converts to the specified compound in vivo after administration to a patient.
Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H.
Bundgaard, Elsevier, 1985.
Where the compounds according to embodiments of this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. The skilled artisan will understand that the term compound as used herein, is meant to include solvated compounds of Formula (I).
Where the processes for the preparation of the compounds according to certain embodiments of the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography.
The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
One embodiment of the present invention is directed to a composition, including a pharmaceutical composition, comprising, consisting of, and/or consisting essentially of the (+)-enantiomer of a compound of formula (I) wherein said composition is substantially free from the (-)-isomer of said compound. In the present context, substantially free means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (-)-isomer calculated as % (+) -enantiomer = (mass (+) - enantiomer) X100 (mass (+) - enantiomer) + (mass(-) - enantiomer) Another embodiment of the present invention is a composition, including a pharmaceutical composition, comprising, consisting of, and consisting essentially of the (-)-enantiomer of a compound of formula (I) wherein said composition is substantially free from the (+)-isomer of said compound. In the present context, substantially free from means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (+)-isomer calculated as % (-) - enantiomer = (mass (-) - enantiomer) x 100 (mass (+) - enantiomer) + (mass(-) - enantiomer) During any of the processes for preparation of the compounds of the various embodiments of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, Second Edition, J.F.W. McOmie, Plenum Press, 1973;
T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley &
Sons, 1991; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Even though the compounds of embodiments of the present invention (including their pharmaceutically acceptable salts and pharmaceutically acceptable solvates) can be administered alone, they will generally be administered in admixture with a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient and/or a pharmaceutically acceptable diluent selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. Thus, particular embodiments of the present invention are directed to pharmaceutical and veterinary compositions comprising compounds of formula (I) and at least one pharmaceutically acceptable carrier, pharmaceutically acceptable excipient, and/or pharmaceutically acceptable diluent.
By way of example, in the pharmaceutical compositions of embodiments of the present invention, the compounds of formula (I) may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s), and combinations thereof Solid oral dosage forms, such as tablets or capsules, containing the compounds of the present invention may be administered in at least one dosage form at a time, as appropriate. It is also possible to administer the compounds in sustained release formulations.
Additional oral forms in which the present inventive compounds may be administered include elixirs, solutions, syrups, and suspensions; each optionally containing flavoring agents and coloring agents.
Alternatively, compounds of formula (I) can be administered by inhalation (intratracheal or intranasal) or in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder.
For example, they can be incorporated into a cream comprising, consisting of, and/or consisting essentially of an aqueous emulsion of polyethylene glycols or liquid paraffin.
They can also be incorporated, at a concentration of between about 1 % and about 10 %
by weight of the cream, into an ointment comprising, consisting of, and/or consisting essentially of a white wax or white soft paraffin base together with any stabilizers and preservatives as may be required. An alternative means of administration includes transdermal administration by using a skin or transdermal patch.
The pharmaceutical compositions of the present invention (as well as the compounds of the present invention alone) can also be injected parenterally, for example intracavernosally, intravenously, intramuscularly, subcutaneously, intradermally or intrathecally. In this case, the compositions will also include at least one of a suitable carrier, a suitable excipient, and a suitable diluent.
For parenteral administration, the pharmaceutical compositions of the present invention are best used in the form of a sterile aqueous solution that may contain other substances, for example, enough salts and monosaccharides to make the solution isotonic with blood.
For buccal or sublingual administration, the pharmaceutical compositions of the present invention may be administered in the form of tablets or lozenges, which can be formulated in a conventional manner.
By way of further example, pharmaceutical compositions containing at least one of the compounds of formula (I) can be prepared by mixing the compound(s) with a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, and/or a pharmaceutically acceptable excipient according to conventional pharmaceutical compounding techniques. The carrier, excipient, and diluent may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral, etc.).
Thus for liquid oral preparations, such as suspensions, syrups, elixirs and solutions, suitable carriers, excipients and diluents include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and tablets, suitable carriers, excipients and diluents include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations also may be optionally coated with substances, such as, sugars, or be enterically -coated so as to modulate the major site of absorption and disintegration. For parenteral administration, the carrier, excipient and diluent will usually include sterile water, and other ingredients may be added to increase solubility and preservation of the composition. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives, such as solubilizers and preservatives.
A therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition thereof includes a dose range from about 0.1 mg to about 3000 mg, or any amount or range therein, in particular from about 1 mg to about 1000 mg, or any amount or range therein, more particularly, from about 10 mg to about 500 mg, or any amount or range therein, of ingredient compound of formula (I) in a regimen of about 1 to 4 times per day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for a compound of formula (I) will vary as will the diseases, syndromes, conditions, and disorders being treated.
For oral administration, a pharmaceutical composition is preferably provided in the form of tablets containing about 0.01, about 10, about 50, about 100, about 150, about 200, about 250, and about 500 milligrams of a compound of formula (I).
Advantageously, a compound of formula (I) may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three and four times daily.
Optimal dosages of a compound of formula (I) to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease, syndrome, condition, or disorder. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to achieve an appropriate therapeutic level and desired therapeutic effect. The above dosages are thus exemplary of the average case.
There can be, of course, individual instances wherein higher or lower dosage ranges are merited, and such are within the scope of this invention.
One skilled in the art will recognize that, both in vivo and in vitro trials using suitable, known and generally accepted cell and / or animal models are predictive of the ability of a test compound to treat or prevent a given disorder. One skilled in the art will further recognize that human clinical trails including first-in-human, dose ranging and efficacy trials, in healthy patients and / or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.
A compound of formula (I) may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of a compound of formula (I) is required for a subject in need thereof.
GENERAL SYNTHETIC METHODS
Representative compounds of the present invention may be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the specific chemical reactions and specific conditions described in the schemes and examples. The various starting materials used in the schemes are commercially available or may be prepared by methods well within the skill of persons versed in the art. The variables are as defined herein and within the skill of persons versed in the art.
Abbreviations used in the specification, particularly the Schemes and Examples, are as follows:
DCC = N,N-Dicyclohexylcarbodiimide DCM = Dichloromethane DIPEA or DIEA = Diisopropylethylamine DMF = N,N-Dimethylformamide DMSO = Dimethylsulfoxide EDTA = Ethylenediaminetetraacetic acid EtOAc = Ethyl Acetate HATU = O-(7-Azabenzotriazol-1-yl)-N,N,N",N"-Tetramethyl Uronium Hexafluorophosphate HBTU = O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate HEPES = 4-(2-Hydroxyethyl)-1-piperazineethane sulfonic acid TEA = Triethylamine TFA = Trifluoroacetic Acid THE = Tetrahydrofuran The compounds of Formula (I) of the present invention may be prepared according to the process as outlined in Scheme 1, below.
R H3CO3S --ON-PG1 '~-\ N NH
\ I
W (VI) (V) \N N-PG1 N N NH
\C\-N W W
(VII) (VIII) Z N \N N
\~ X
(IX) I ~Y
(I) / Z
Scheme 1 Accordingly, a suitably substituted compound of formula (V), a known compound or compound prepared by known methods, is reacted with a suitably substituted compound of formula (VI), wherein PG1 is a suitably selected nitrogen protecting group such as -CH(phenyl)2, benzyl, t-butyl, methyl, and the like, preferably -CH(phenyl)2, a known compound or compound prepared by known methods; in the presence of an organic base such as DIPEA, pyridine, and the like (preferably not TEA); in an organic solvent such as acetonitrile, THF, DCM, and the like;
preferably at a temperature in the range of from about 50 C to about 90 C; to yield the corresponding compound of formula (VII).
The compound of formula (VII) is de-protected according to known methods, to yield the corresponding compound of formula (VIII). For example, wherein PG1 is -CH(phenyl)2, the compound of formula (VII) is de-protected by reacting with 1-chloroethyl chloroformate, in an organic solvent such as dichloromethane, and then refluxed in an organic solvent such as methanol, to yield the corresponding compound of formula (VIII).
The compound of formula (VIII) is reacted with a suitably substituted compound of formula (IX), wherein LG1 is selected from the group consisting of -C(O)Cl and C(O)OH, and wherein LG1 is bound at the desired bonding position on benzene ring of the the benzo-fused portion of the compound of formula (IX), a known compound or compound prepared by known methods, in the presence of a suitably selected coupling agent such as HATU, HBTU, DCC, and the like; in the presence of a suitably selected organic base such as DIPEA, TEA, pyridine, and the like; in an organic solvent such as acetonitrile, DMF, DCM, and the like; to yield the corresponding compound of formula (I).
The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.
In the Examples which follow, some synthesis products are listed as having been isolated as a residue. It will be understood by one of ordinary skill in the art that the term "residue" does not limit the physical state in which the product was isolated and may include, for example, a solid, an oil, a foam, a gum, a syrup, and the like.
Example 1: (2-Cyclohexyl-benzooxazol-6-yl)-f3-(4-pyridin-2-yl-piperazin-1-yl)-azetidin-1-yll-methanone O
O
N / N
NJ
STEP A: 2-Cyclohexyl-benzooxazole-6-carboxylic acid To a solution of 4-amino-3-hydroxy-benzoic acid methyl ester (5 g, 29.91 mmol) in CH3OH (150 mL) was added cyclohexanecarbaldehyde (3.6 mL, 29.91 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h. The solvent was removed by evaporation and CH3CN (150 mL) was added to the residue. Lead (IV) acetate (13.26 g, 29.91 mmol) was added as one portion under N2 and the resulting mixture was refluxed for 10 min. After cooling, the resulting solid was filtered and washed with CH3CN. To the filtrate was then added 3N NaOH (40 mL). The resulting mixture was stirred at 50 C for 18 h. The solvent was removed by evaporation and the resulting residue was purified by flash chromatography on silica gel to yield 2-cyclohexyl-benzooxazole-6-carboxylic acid. MS m/z (M+H+) 246.2.
STEP B: (2-Cyclohexyl-benzooxazol-6-yl)-(3-hey-azetidin-1-yl)-methanone To a solution of 2-cyclohexyl-benzooxazole-6-carboxylic acid (0.47 g, 1.9 mmol) and HBTU (0.94 g, 2.5 mmol) in DMF (10 mL) was added DIPEA (1.4 mL, 7.6 mmol). The resulting mixture was stirred at room temperature for 10 min, and then the hydrochloride salt of azetidin-3-ol (0.452 g, 4.7 mmol) was added. The resulting mixture was stirred at room temperature for 1 h, and then purified by reverse phase liquid chromatography. Fractions containing product were lyophilized to yield (2-cyclohexyl-benzooxazol-6-yl)-(3-hydroxy-azetidin-1-yl)-methanone. MS m/z (M+H+) 301.
STEP C: 2-Cyclohex. {[3-(4-pyridin-2-yllpiperazin-1-yl)azetidin-1-yl]carbony}-1,3-benzoxazole Methanesulfonyl chloride (0.152 mL, 1.9 mmol) was added dropwise to a solution of (2-cyclohexyl-benzooxazol-6-yl)-(3-hydroxy-azetidin-1-yl)-methanone (0.48 g, 1.6 mmol) and DIPEA (0.558 mL, 3.2 mmol) in DCM (20 mL) at -40 C
under nitrogen. Immediately following the addition, the cooling bath was removed and the mixture slowly warmed to room temperature. The resulting mixture was then washed with water, dried using magnesium sulfate, filtered, and the solvent removed under reduced pressure. The resulting residue was dissolved in acetonitrile (1 mL).
DIPEA
(0.41 mL, 2.4 mmol) and N-(2-pyridyl)piperazine (1.6 mmol) were added. The resulting mixture was then microwaved at 160 C for 4 hours. DMF (3 mL) was added to the resulting mixture, which was then purified by reverse phase liquid chromatography. The fractions containing product were diluted with IN HCl (5 mL) and then lyophilized to yield 2-cyclohexyl-6-{[3-(4-pyridin-2-ylpiperazin-1-yl)azetidin-1-yl]carbonyl}-1,3-benzoxazole as its corresponding hydrochloride salt.
1H NMR (400MHz, DMSO-d6) 6= 9.21 (s, 1 H), 8.15 (d, J= 5.1 Hz, 1 H), 7.96 (d, J= 8.3 Hz, 1 H), 7.81 (br. s., 1 H), 7.16 - 7.22 (m, 1 H), 7.06 (d, J= 8.3 Hz, 1 H), 6.88 (s, 1 H), 4.54 (br. s., 2 H), 4.38 (d, J= 6.6 Hz, 2 H), 4.13 (br. s., 1 H), 3.73 (br. s., 8 H), 3.31 - 3.60 (m, 1 H), 1.77 (d, J= 13.7 Hz, 4 H), 1.65 (br. s., 1 H), 1.32 - 1.44 (m, 2 H), 1.15 - 1.32 (m, 2 H), 1.06 (t, J= 7.0 Hz, 1 H). MS m/z (M+H+) 446.
Compounds #2 through 28 may be similarly prepared according to the procedures as described in Example 1, above and substituting suitably selected and / or substituted reagents, starting materials and purification methods known to those skilled in the art.
Example 2: (in vitro Assay): MGL Enzyme Activity Assay All rate-based assays were performed in black 384-well polypropylene PCR
microplates (Abgene) in a total volume of 30 L. Substrate 4-methylumbelliferyl butyrate (4MU-B, Sigma) and purified mutant MGL enzyme (mut-MGLL 11-313 L179S L186S) were diluted separately into 20 mM PIPES buffer (pH 7), containing 150 mM NaCl, and 0.001% Tween 20. Compounds of Formula (I) were pre-dispensed (50 nL) into the assay plate using a Cartisian Hummingbird (Genomic Solutions, Ann Arbor, MI) prior to adding 4MU-B (25 pL of 1.2X solution, final concentration of 10 M) followed by enzyme (5 pL of a 6X solution, final concentration of 5 nM) to initiate the reaction. Final compound concentrations ranged from 17 to 0.0003 M.
The fluorescence change due to 4MU-B cleavage was monitored with excitation and emission wavelengths of 335 and 440 nm, respectively, and a bandwidth of 10 nm (Safire2, Tecan) at 37 C for 5 min.
The IC50 values for compounds of Formula (I) were determined using Excel from a fit of the equation to the concentration- response-plot of the fractional activity as a function of inhibitor concentration.
Example 3: (in vitro Assay): MGL ThermoFluor Assay The ThermoFluor (TF) assay is a 384-well plate-based binding assay that measures thermal stability of proteins (Pantoliano, M. W., Petrella, E. C., Kwasnoski, J.
D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B.
A., Lane, P., and Salemme, F. R. JBiomol Screen 2001, 6, 429-40; Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. Biochemistry 2005, 44, 5258-66). The experiments were carried out using instruments available from Johnson & Johnson Pharmaceutical Research & Development, LLC. TF dye used in all experiments was 1,8-ANS
(Invitrogen: A-47). Final TF assay conditions used for MGL studies were 0.07 mg/ml of purified mutant MGL (mut-MGLL 11-313 L179S L186S), 100 M ANS, 200 mM
NaCl, 0.001% Tween-20 in 50 mM PIPES (pH = 7.0).
Screening compound plates contained 100% DMSO compound solutions at a single concentration. For follow-up concentration-response studies, compounds were arranged in a pre-dispensed plate (Greiner Bio-one: 781280), wherein compounds were serially diluted in 100% DMSO across 11 columns within a series. Columns 12 and 24 were used as DMSO reference and contained no compound. For both single and multiple compound concentration-response experiments, the compound aliquots (50 nL) were robotically pre-dispensed directly into black 384-well polypropylene PCR
microplates (Abgene: TF-03 84/k) using the Cartesian Hummingbird liquid handler (Genomic Solutions, Ann Arbor, MI). . Following compound dispense, protein and dye solutions were added to achieve the final assay volume of 3 L. The assay solutions were overlayed with 1 pL of silicone oil (Fluka, type DC 200: 85411) to prevent evaporation.
Bar-coded assay plates were robotically loaded onto a thermostatically controlled PCR-type thermal block and then heated from 40 to 90 C degrees at a ramp-rate of 1 C/min for all experiments. Fluorescence was measured by continuous illumination with UV light (Hamamatsu LC6) supplied via fiber optics and filtered through a band-pass filter (380-400 nm; > 6 OD cutoff). Fluorescence emission of the entire 384-well plate was detected by measuring light intensity using a CCD
camera (Sensys, Roper Scientific) filtered to detect 500 25 nm, resulting in simultaneous and independent readings of all 384 wells. A single image with 20-sec exposure time was collected at each temperature, and the sum of the pixel intensity in a given area of the assay plate was recorded versus temperature and fit to standard equations to yield the Tm. (Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R., JBiomol Screen 2001, 6, 429-40).
Example 4: 2-AG Accumulation assay HeLa cells were homogenated with a Polytron in 10 ml (about 400 million cells) HEPES buffer (HEPES 20 mM, pH 7.4, NaCl 125 mM, EDTA 1 mM, KC15 mM, Glucose 20 mM). The homogenate from 20 million cells (0.5 ml) was incubated with MGL inhibitor for 15 min to block MGL activity and then the HEPES buffer solution was incubated with calcium (10 mM) for 20 min. The total reaction volume was 5 ml. The reactions were stopped by 6 mL organic solvent extraction (2:1 chloroform/methanol). Methoxy arachidonyl fluorophosphonate (MAFP) was used as positive control. In the absence of MAFP the 2-AG levels are about 3.4 pmol/sample.
In the presence of 100 nM MAFP 2-AG levels increase to 174 pmol/sample.
Accumulated 2-AG in the organic phase was measured by a HPLC/MS method, according to the following equation: %MAFP = (Compound 2-AG/MAFP 2-AG) x 100.
Representative compounds of formula (I) were tested according to the procedure as described in Example 2, 3 and 4 above, with results as listed in Table 4.
Table 4 Example 4 Example 4 Example 2 Example 3 % MAFP @ % MAFP @
Cmpd No. IC50 ( M) Kd ( M) 1 M 10 M
1 0.031 0.001 2 0.050 0.130 39.7 87.6 3 0.055 0.091 45.7 82.9 4 0.060 0.002 0.077 0.008 82.9 6 0.100 0.048 30.6 68.8 7 0.186 0.083 79.5 8 0.220 0.330 72.9 9 0.230 0.040 67.8 0.330 0.020 160.1 11 0.350 0.010 160.1 12 0.360 5.000 142.0 13 0.430 0.030 93.5 14 0.440 5.000 53.7 0.470 1.850 57.6 16 0.810 4.550 61.1 17 0.880 4.000 25.9 18 0.920 0.050 134.6 19 1.073 0.172 19.9 47.3 1.340 5.560 86.9 21 1.420 6.670 29.2 22 1.670 5.560 50.1 23 1.890 2.500 84.5 24 1.980 5.000 58.8 3.810 6.670 65.8 26 5.460 11.110 37.0 27 9.441 28.569 76.3 28 0.090 77.0 Example 5: Oral Formulation - Prophetic Example As a specific embodiment of an oral composition, 100 mg of the compound #1, prepared as in Example 1 is formulated with sufficient finely divided lactose to provide 5 a total amount of 580 to 590 mg to fill a size 0 hard gel capsule.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.
Claims (15)
1. A method of treating or ameliorating a disease, syndrome, condition or disorder that is affected by the inhibition of MGL, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (I) selected from the group consisting of a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is isobutyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclohexylmethyl, and R3 is hydrogen;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 2-methoxyphenylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is n-propyl, and R3 is methyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is t-butyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-methoxyphenyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(W)-N(R3)-, W is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, W is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is CH, R1 is 4-fluoro, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is t-butyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -NH-C(R2)-C(R3)-, R2 is 4-methylphenyl and R3 is methoxy-methyl-carbonyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is isobutyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclohexylmethyl, and R3 is hydrogen;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 2-methoxyphenylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is n-propyl, and R3 is methyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is t-butyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-methoxyphenyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(W)-N(R3)-, W is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, W is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is CH, R1 is 4-fluoro, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is t-butyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -NH-C(R2)-C(R3)-, R2 is 4-methylphenyl and R3 is methoxy-methyl-carbonyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
2. A method as in Claim 1, wherein the compound of formula (I) is selected form the group consisting of a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is isobutyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclohexylmethyl, and R3 is hydrogen;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 2-methoxyphenylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is n-propyl, and R3 is methyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is isobutyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclohexylmethyl, and R3 is hydrogen;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 2-methoxyphenylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is n-propyl, and R3 is methyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
3. A method as in Claim 1, wherein the compound of formula (I) is selected form the group consisting of a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is 4-methylphenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
4. A method as in Claim 1, wherein the compound of formula (I) is selected form the group consisting of a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-methoxyphenyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -NH-C(R2)-C(R3)-, R2 is 4-methylphenyl and R3 is methoxy-methyl-carbonyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-methoxyphenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is 2,2-dimethylpropyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenoxymethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is cyclopentylmethyl, and R3 is methyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenyl, and R3 is isobutyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-methoxyphenyl;
a compound wherein W is CH, R1 is 2-methoxy, is X-Y-Z is -CH-C(R2)-N(R3)-, R2 is phenylmethyl, and R3 is cyclohexylmethyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -NH-C(R2)-C(R3)-, R2 is 4-methylphenyl and R3 is methoxy-methyl-carbonyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -CH-C(R2)-N(R3), R2 is n-propyl and R3 is cyclohexylmethyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof
5. a method as in Claim 1, wherein the compound of formula (I) is selected form the group consisting of a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is cyclohexyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is t-butyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 3-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is 4-fluorophenyl;
a compound wherein W is N, R1 is H, is X-Y-Z is -O-C(R2)=N-, and R2 is t-butyl;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
6. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is selected from the group consisting of pain, inflammatory pain, inflammatory hypersensitivity conditions and neuropathic pain.
7. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is pain.
8. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is inflammatory pain.
9. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is visceral pain.
10. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is ulcerative colitis.
11. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is neuropathic pain.
12. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is neuropathic cold allodynia.
13. A method as in Claim 1, wherein the disease, syndrome, condition or disorder that is affected by inhibition of MGL is selected from the group consisting of inflammatory pain and neuropathic pain.
14. The use of a compound as in Claim 1 for the preparation of a medicament or pharmaceutical composition for the treatment of the disease, syndrome, condition or disorder that is affected by inhibition of MGL, in a subject in need thereof.
15. The use of a compound as in Claim 1 for the preparation of a medicament or pharmaceutical composition for the treatment of inflammatory pain or neuropathic pain, in a subject in need thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17166109P | 2009-04-22 | 2009-04-22 | |
US61/171,661 | 2009-04-22 | ||
PCT/US2010/032100 WO2010124122A1 (en) | 2009-04-22 | 2010-04-22 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2759706A1 true CA2759706A1 (en) | 2010-10-28 |
Family
ID=42226535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2759706A Abandoned CA2759706A1 (en) | 2009-04-22 | 2010-04-22 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2421535A1 (en) |
JP (1) | JP2012524810A (en) |
KR (1) | KR20120005517A (en) |
CN (1) | CN102458407B (en) |
AU (1) | AU2010238746B2 (en) |
BR (1) | BRPI1014874A2 (en) |
CA (1) | CA2759706A1 (en) |
IL (1) | IL215797A0 (en) |
RU (1) | RU2011147201A (en) |
TW (1) | TW201103914A (en) |
WO (1) | WO2010124122A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2760450A1 (en) * | 2011-09-30 | 2014-08-06 | Janssen Pharmaceutica, N.V. | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders |
EP2935294A4 (en) * | 2012-12-21 | 2016-08-31 | Univ California | Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity |
EP3087067B1 (en) | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
US10106556B2 (en) | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
TWI738753B (en) | 2016-03-31 | 2021-09-11 | 日商武田藥品工業股份有限公司 | Heterocyclic compound |
US10610520B2 (en) | 2016-03-31 | 2020-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
BR112020005720A2 (en) | 2017-09-29 | 2020-10-20 | Takeda Pharmaceutical Company Limited | compound or salt, medication, methods for inhibiting monoacylglycerol lipase and for the prophylaxis or treatment of alzheimer's disease, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, anxiety disorder, pain, epilepsy or depression, and, use of compost or salt. |
TW201936602A (en) | 2017-11-28 | 2019-09-16 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
TW201930300A (en) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2915199B1 (en) * | 2007-04-18 | 2010-01-22 | Sanofi Aventis | TRIAZOLOPYRIDINE-CARBOXAMIDE AND TRIAZOLOPYRIMIDINE-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
EP2180048B1 (en) * | 2008-10-09 | 2014-12-17 | Janssen Pharmaceutica N.V. | Alternative crystal form of monoacylglycerol lipase (MGLL) |
-
2010
- 2010-04-22 EP EP10714829A patent/EP2421535A1/en not_active Withdrawn
- 2010-04-22 RU RU2011147201/15A patent/RU2011147201A/en not_active Application Discontinuation
- 2010-04-22 BR BRPI1014874A patent/BRPI1014874A2/en active Search and Examination
- 2010-04-22 TW TW099112745A patent/TW201103914A/en unknown
- 2010-04-22 KR KR1020117027431A patent/KR20120005517A/en not_active Application Discontinuation
- 2010-04-22 WO PCT/US2010/032100 patent/WO2010124122A1/en active Application Filing
- 2010-04-22 CN CN201080028761.8A patent/CN102458407B/en not_active Expired - Fee Related
- 2010-04-22 JP JP2012507395A patent/JP2012524810A/en active Pending
- 2010-04-22 CA CA2759706A patent/CA2759706A1/en not_active Abandoned
- 2010-04-22 AU AU2010238746A patent/AU2010238746B2/en not_active Ceased
-
2011
- 2011-10-23 IL IL215797A patent/IL215797A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2421535A1 (en) | 2012-02-29 |
JP2012524810A (en) | 2012-10-18 |
IL215797A0 (en) | 2012-01-31 |
BRPI1014874A2 (en) | 2016-04-12 |
TW201103914A (en) | 2011-02-01 |
CN102458407B (en) | 2014-03-05 |
AU2010238746A1 (en) | 2011-11-10 |
KR20120005517A (en) | 2012-01-16 |
WO2010124122A1 (en) | 2010-10-28 |
AU2010238746B2 (en) | 2015-02-19 |
RU2011147201A (en) | 2013-05-27 |
CN102458407A (en) | 2012-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8729064B2 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | |
AU2010238746B2 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | |
EP2611774B1 (en) | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | |
US8637498B2 (en) | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | |
EP2421852B9 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
US8748417B2 (en) | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | |
KR20130142137A (en) | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | |
US8513423B2 (en) | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20150421 |
|
FZDE | Discontinued |
Effective date: 20170712 |